

ISPOR Asia Pacific 2018

The leading Asia Pacific conference for health economics and outcomes research

8 - 11 September
Keio Plaza Hotel
Tokyo, Japan



*Moving Into Action: Informing Policy
and Strengthening Healthcare
Systems in Asia Pacific*


 #ISPORTokyo

NETWORK: ISPOR / WI-FI PASSWORD: TOKYO2018

 ISPOR

www.ispor.org

HEOR is changing at a rapid pace. Let ISPOR guide you through it.



Join a global network of more than 20,000 healthcare professionals who are improving healthcare decisions

Members enjoy:

- Admission to a global network of diverse healthcare stakeholders
- Access to healthcare's key influencers, from payers and providers to researchers and patients
- Discounts on event registrations
- Subscriptions to all ISPOR publications
- Special awards and recognition
- Exclusive online HEOR tools and cutting-edge science
- Knowledge-sharing opportunities with ISPOR colleagues

Become a member today at
www.ispor.org/membership

New to the field? Explore ISPOR member perks like private career development resources, members-only education and training programs, and exclusive networking opportunities!

Dear Colleagues,

On behalf of the ISPOR Asia Consortium Executive Committee, it is my pleasure to welcome you to the ISPOR Asia Pacific 2018 Conference.



This is a truly significant event, as it represents the 15th anniversary since ISPOR's inaugural Asia Pacific Conference in Kobe, Japan in 2003. At that time, ISPOR was just beginning its presence in the Asia Pacific region, and around 250 delegates attended the Kobe Conference. Immediately following the conference, the ISPOR Asia Consortium was established with 13 founding members as the prototype of regional leadership in globalizing ISPOR, committing to furthering ISPOR's mission in the Asia Pacific region. After 14 years of hard work and commitment by our colleagues, the ISPOR Asia Consortium has now grown to 1,000 members and the ISPOR Asia Pacific 2018 Conference is expected to be the largest ISPOR Asia Pacific Conference ever, with over 1,500 global delegates expected and over 950 presentations featured (a 38% increase in abstracts submitted from Singapore 2016).

ISPOR's astounding growth regionally could not have happened without the support of ISPOR Asia Consortium and its membership. The Consortium, along with the ISPOR regional chapter members in Asia Pacific, have been instrumental in developing and supporting many impactful regional HEOR initiatives including publications such as *Value in Health Regional Issues*, the regional ISPOR journal recently accepted for Medline indexing, and *News Across Asia*, the quarterly newsletter of ISPOR Asia Consortium. Members also have contributed prolifically to the global body of research and developed regional HEOR conferences and trainings to build much needed capacity. ISPOR and Asia Consortium have further helped to bridge the knowledge gaps by creating effective platforms to share critical information and promote stakeholders engagement, such as the annual ISPOR HTA Roundtable in Asia Pacific and the ISPOR Patient Roundtable.

As HEOR and HTA continue to grow in importance for all healthcare stakeholders in Asia Pacific, ISPOR is deeply committed to supporting improved global healthcare decision making and outcomes. I invite you to get involved in the Society and contribute to this important mission.

I am excited to have the ISPOR Asia Pacific Conference return to Japan, particularly during this dynamic time of national debate surrounding the HTA pilot program. I am confident this Conference will provide ample opportunity for you to learn and discuss these important issues. Thank you for participating in ISPOR Asia Pacific 2018. I wish you a successful and fruitful conference—and enjoy your time in Japan.

Best regards,

A handwritten signature in black ink, reading '鎌江伊三夫' (Kamae Isao).

Isao Kamae, MD, DrPH

2016-2018 Chair, ISPOR Asia Consortium Executive Committee, and Project Professor of Health Policy and Technology Assessment, Graduate School of Public Policy, The University of Tokyo, Tokyo, Japan

ISPOR Asia Pacific 2018

8 – 11 September
Tokyo, Japan



Table of Contents


LETTER FROM ASIA CONSORTIUM EXECUTIVE COMMITTEE CHAIR	3
LETTER FROM ISPOR ASIA PACIFIC 2018 CONFERENCE PROGRAM CO-CHAIRS	5
CONFERENCE PROGRAM COMMITTEE	6
LETTER FROM ISPOR PRESIDENT	7
CONFERENCE-AT-A-GLANCE	8
CONFERENCE SUPPORTING INSTITUTIONS	10
EVENT SPONSORS	10
PLENARY SESSIONS	12
SCHEDULE OF EVENTS	
● SATURDAY, 8 SEPTEMBER	14
● SUNDAY, 9 SEPTEMBER	16
● MONDAY, 10 SEPTEMBER	20
● TUESDAY, 11 SEPTEMBER	25
INVITATIONAL GROUP MEETINGS	29
RESEARCH POSTER OVERVIEW	32
EXHIBIT PROGRAM OVERVIEW	33
EXHIBITOR DIRECTORY	33
EXHIBIT/POSTER HALL FLOOR PLAN	34
KEY INFORMATION	36
CONFERENCE ROOMS FLOOR PLAN	38

Dear Colleagues,

We extend you a warm welcome to Tokyo for the ISPOR Asia Pacific 2018 Conference. As the leading health economics and outcomes research (HEOR) conference in Asia Pacific, ISPOR Asia Pacific 2018 will address many critical healthcare issues surrounding the pursuit of improving efficiency, quality, safety, and access to health technologies while controlling healthcare costs. ISPOR Asia Pacific 2018 has been designed for professionals who want to stay ahead of the latest trends in the field of HEOR, and it provides a unique scientific platform to facilitate interactions among stakeholders to learn the foremost in HEOR development and share best practices for its use.



Fukuda



Saito



Ikeda



Zhao

With the theme “Moving into Action: Informing Policy and Strengthening Healthcare Systems in Asia Pacific,” the ISPOR Asia Pacific 2018 Conference features distinguished speakers and 3 thought-provoking plenary sessions focusing on timely and important issues facing healthcare systems across Asia Pacific. The first plenary, “Transforming Healthcare and Leveraging Digital Health for Better Health in Asia Pacific” explores the current challenges and possibilities in digital health in Asia Pacific, with valuable insight about how to grasp benefits and potential from those furthest in their digital journey. The second plenary, “Real World Evidence in Asia Pacific: Are We Ready? Is It Helpful for Decision Makers?” discusses the situation surrounding real-world evidence (RWE) and its potential value, examines readiness of RWE in healthcare decision making in the region, and explores how we should approach RWE to get the most out of it. The third plenary, “Risk Sharing Agreements: Country Experiences, Challenges, and Lessons Learned” talks about the use of risk sharing agreements to manage costs, mitigate risk, and improve patient access to innovative therapies. In addition to the plenaries, the program also includes a broad array of short courses, issue panels, workshops, and research presentations, as well as an eye-catching Welcome Reception celebrating Japanese culture and many invaluable networking opportunities with global colleagues.

We are heartened to see so many colleagues from Asia Pacific and around the world all in one place! Your strong support and active participation have made ISPOR Asia Pacific 2018 a record-breaking event. We would like to take this opportunity to thank our Program Review Committee Co-chairs, Local Review Committee members, and peer reviewers who have worked extremely hard to prepare this outstanding conference. We also wish to acknowledge the ISPOR Japan Chapter for its great support and leadership toward contributing to the Conference. Finally, we thank you the ISPOR members who support the important mission of the Society around the globe.

Enjoy ISPOR Asia Pacific 2018 and have a memorable time visiting the Tokyo metropolitan area.

Sincerely,

Takashi Fukuda, PhD

Director, Center for Outcomes Research and Economic Evaluation for Health, National Institute of Public Health Saitama, Japan

Shunya Ikeda, MD, MS, DrMedSci

Vice Dean and Professor of Public Health, School of Medicine, International University of Health and Welfare Narita, Japan

Shinya Saito, MD, PhD

Professor, Graduate School of Health Sciences Okayama University, Okayama, Japan

Kun Zhao, MD, PhD, MHSc

Professor & Director, Division of Health Policy Evaluation and Technology Assessment, China National Health Development Research Center National Health Commission, Beijing, China

Conference Program Committee

ISPOR thanks the Conference Program Committee for its contributions in developing the scientific community's leading HEOR program.

CONFERENCE CO-CHAIRS:



Takashi Fukuda, PhD, Director, Center for Outcomes Research and Economic Evaluation for Health, National Institute of Public Health, Saitama, Japan



Shinya Saito, MD, PhD, Professor, Graduate School of Health Sciences, Okayama University, Okayama, Japan

PROGRAM COMMITTEE CO-CHAIRS:



Shunya Ikeda, MD, MS, DrMedSci, Vice Dean and Professor of Public Health, School of Medicine, International University of Health and Welfare, Narita, Japan



Kun Zhao, MD, PhD, MHSc, Professor & Director, Division of Health Policy Evaluation and Technology Assessment, China National Health Development Research Center, National Health Commission, Beijing, China

RESEARCH REVIEW COMMITTEE CO-CHAIRS:



Paul Scuffham, PhD, Professor in Health Economics, Director of the Centre for Applied Health Economics (School of Medicine), and Deputy Director of the Menzies Health Institute, Queensland, Australia



Jing Wu, PhD, Professor, Pharmaceutical Economics and Policy, Tianjin University, Tianjin, China



Eui-Kyung Lee, PhD, RPh, Professor of Pharmaceutical Policy and Outcomes Research, Sungkyunkwan University, Seoul, South Korea



Christopher Carswell, MSc, Editor-in Chief, PharmacoEconomics, Springer Nature, Auckland, New Zealand

ISSUE PANEL REVIEW COMMITTEE CO-CHAIRS:



Vivian WY Lee, BSc, PharmD, BCPS, (Added Qualification in Cardiology), Associate Professor, School of Pharmacy, and Assistant Dean (Student Development), Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong



Bhagwan Aggarwal, PhD, MBA, MSc, MPhil, BSc, Assistant Director & Head of Department, Environmental Carcinogen Unit / Molecular Biology, National Institute of Occupational Health, Indian Council of Medical Research, Almedabad, India

WORKSHOP REVIEW COMMITTEE CO-CHAIRS:



Nathorn Chaiyakunapruk, PharmD, PhD, Professor of Health Economics, School of Pharmacy, Monash University Malaysia, Selangor, Malaysia



Hui-Chu Lang, PhD, Professor, Institute of Hospital and Health Care Administration, National Yang-Ming University, Taipei, Taiwan

LOCAL PROGRAM REVIEW COMMITTEE MEMBERS:



Hiroyuki Sakamaki, PhD, Professor, Department of Management, School of Management, Tokyo University of Science, Tokyo, Japan



Kojiro Shimozuma, MD, PhD, Professor, Division of Health Services Research, Department of Biomedical Sciences, College of Life Sciences, Ritsumeikan University, Kusatsu, Japan



Hiroyuki Okumura, PhD, Associate Director & Medical Science Staff, Medical Affairs, QA, RA and Pharmacovigilance, Astellas Pharma Inc., Tokyo, Japan



Chisato Hamashima, MD, PhD, Section Head, Teikyo University, Tokyo, Japan



Manabu Akazawa, PhD, Professor, Public Health and Epidemiology, Meiji Pharmaceutical University, Tokyo, Japan



Shinichi Noto, MS, PhD, Professor, Niigata Sogo Gakuen School Corporation, Niigata University of Health and Welfare, Niigata, Japan



Shuichi Yamaguchi, HTA Group Manager, External Affairs Department, Chugai Pharmaceutical Co., Ltd., Tokyo, Japan



Ataru Igarashi, PhD, MS, Associate Professor, Department of Drug Policy and Management, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan



Takeru Shiroiwa, PhD, Senior Researcher, Department of Health and Welfare Services, National Institute of Public Health, Saitama, Japan

Dear Colleagues,

As President of ISPOR, it is my great pleasure to welcome you to the ISPOR Asia Pacific 2018 Conference. I am very impressed to see the remarkable growth of ISPOR in Asia Pacific, with over 1,500 delegates expected at the Conference. This incredible conference in Asia Pacific is a prime example of ISPOR's dynamic global presence and commitment to the Society's mission of promoting health economics and outcomes research excellence to improve decision making for health globally. Apart from the international, European and regional conferences in Asia and Latin America, ISPOR also holds annual stakeholder roundtables on HTA and patient engagement around the globe, and engages members and stakeholders through its regional groups.



As a truly global organization, ISPOR has more than 20,000 international members including regional chapter members from over 120 countries. We currently have 86 regional chapters spanning the globe, and ISPOR is also represented by numerous regional groups including the Asia Consortium, Latin America Consortium, Central and Eastern Europe Consortium, Africa Network, and Arabic Network. These groups support ISPOR's mission at the local level and do substantial work generating local research and publications, training, mentoring, network building, and promoting stakeholder engagement.

ISPOR recognizes that needs vary around the globe. With that in mind, we position ourselves accordingly to meet these needs wherever they rise. ISPOR publishes authoritative good practice reports on critical methodologies for HEOR and develops tools for researchers and decision makers. Through our special interest groups, ISPOR engages HEOR researchers to help them contribute global perspectives to topics of importance to the scientific community. And as the science of HEOR expands globally, we are committed to disseminating our good practices and building capacity through our vast network of global experts and regional chapters.

My heartfelt thanks to the Conference Committee members for their outstanding job in putting together this high-quality and interesting program. I also would like to acknowledge the ISPOR Asia Consortium leadership and ISPOR Japan Chapter for their great effort and support. Finally, I wish to recognize the ISPOR staff for their hard work in organizing yet another highly successful conference.

As a valued member and colleague in ISPOR, I thank you for your support and contributions to the Society and wish you a fruitful conference!

Best regards,

A handwritten signature in black ink, consisting of several overlapping loops and lines, characteristic of a cursive or semi-cursive style.

Federico Augustovski, MD, MSc, PhD

ISPOR 2018-2019 President, and Director of Health Economic Evaluations and Technology Assessment, Institute for Clinical Effectiveness and Health Policy, Buenos Aires, Argentina

ISPOR Asia Pacific 2018 Agenda at a Glance

Saturday, 8 September 2018

7:00AM-6:00PM	REGISTRATION HELP DESK HOURS
8:00AM-12:00PM	SHORT COURSE MORNING SESSION
1:00PM-5:00PM	SHORT COURSE AFTERNOON SESSION
5:30PM-6:30PM	EDUCATIONAL SYMPOSIUM
6:45PM-7:45PM	EDUCATIONAL SYMPOSIUM
8:00PM-9:00PM	EDUCATIONAL SYMPOSIUM
9:00PM-10:30PM	WELCOME RECEPTION

Sunday, 9 September 2018

7:00AM-6:00PM	REGISTRATION HELP DESK HOURS
7:00AM-12:00PM	EXHIBITOR MOVE IN
8:00AM-12:00PM	SHORT COURSE MORNING SESSION
12:00PM-6:00PM	SPEAKER READY ROOM HOURS
12:30PM-7:30PM	RESEARCH POSTER PRESENTATIONS – SESSION I
1:00PM-3:15PM	WELCOME, OPENING SPEECH, AND FIRST PLENARY SESSION
3:15PM-3:45PM	BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION I
3:45PM-4:45PM	BREAKOUT SESSION
4:45PM-5:00PM	BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION I
5:00PM-6:00PM	BREAKOUT SESSION
5:00PM-6:00PM	ISPOR STUDENT CAREER EVENT
6:00PM-7:30PM	EXHIBITORS' RECEPTION & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION I
6:15PM-7:15PM	SPOTLIGHT SESSION
6:30PM-7:30PM	POSTER AUTHOR DISCUSSION HOUR – SESSION I
7:30PM-9:00PM	ASIA CONSORTIUM RECEPTION

Monday, 10 September 2018

7:00AM-6:00PM	REGISTRATION HELP DESK HOURS
7:15AM-8:15AM	EDUCATIONAL SYMPOSIUM
8:00AM-6:00PM	SPEAKER READY ROOM HOURS
8:30AM-10:00AM	WELCOME AND SECOND PLENARY SESSION
8:30AM-1:30PM	RESEARCH POSTER PRESENTATIONS – SESSION II

Monday, 10 September 2018 continued

10:00AM-10:30AM	BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION II
10:30AM-11:30AM	BREAKOUT SESSION
11:30AM-2:30PM	LUNCH, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION II
12:00PM-1:00PM	EDUCATIONAL SYMPOSIUM
12:30PM-1:30PM	POSTER AUTHOR DISCUSSION HOUR – SESSION II
1:15PM-2:15PM	EDUCATIONAL SYMPOSIUM
2:30PM-3:30PM	SPOTLIGHT SESSION
2:30PM-7:30PM	RESEARCH POSTER PRESENTATIONS – SESSION III
3:45PM-4:45PM	BREAKOUT SESSION
4:45PM-5:00PM	BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION II
5:00PM-6:00PM	BREAKOUT SESSION
6:00PM-7:30PM	EXHIBITORS' RECEPTION & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION III
6:15PM-7:15PM	BREAKOUT SESSION
6:30PM-7:30PM	POSTER AUTHOR DISCUSSION HOUR – SESSION III

Tuesday, 11 September 2018

7:00AM-5:00PM	REGISTRATION HELP DESK HOURS
7:15AM-8:15AM	EDUCATIONAL SYMPOSIUM
8:00AM-4:00PM	SPEAKER READY ROOM HOURS
8:30AM-10:15AM	WELCOME AND THIRD PLENARY SESSION
8:30AM-1:45PM	RESEARCH POSTER PRESENTATIONS – SESSION IV
10:15AM-10:45AM	BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION IV
10:45AM-11:45AM	BREAKOUT SESSION
11:45AM-2:45PM	LUNCH, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION IV
12:15PM-1:15PM	EDUCATIONAL SYMPOSIUM
12:45PM-1:45PM	POSTER AUTHOR DISCUSSION HOUR – SESSION IV
1:00PM-2:00PM	ISPOR CAREER ADVICE
1:30PM-2:30PM	EDUCATIONAL SYMPOSIUM
2:45PM-3:45PM	BREAKOUT SESSION
4:00PM-5:00PM	BREAKOUT SESSION

Conference Supporting Institutions

Asia Pacific Observatory on Health Systems and Policies
Canon Institute for Global Studies, Tokyo, Japan
Center for Socio-Economic Studies in Pharmacy, Indonesia
Centre for Applied Health Economics Griffith University, Australia
Chalpathi Institute of Pharmaceutical Sciences, India
China Center for Health Economic Research of Peking University, China
China National Health Development Research Center, National Health Commission, China
Chinese University of Hong Kong School of Pharmacy, Hong Kong
Chulalongkorn University, Thailand
Fudan University Center for Pharmacoeconomic Research and Evaluation, China
Health Policy and Technology Assessment Unit, Graduate School of Public Policy, The University of Tokyo, Japan
HTAsiaLink
Institut Sains dan Teknologi Nasional, Faculty of Pharmacy, Indonesia
Institut Teknologi Bandung, School of Pharmacy, Indonesia
Jinan University Pharmaceutical Economics and Health Technology Assessment Research Center, China

Kazakh Association of HTA, Kazakhstan
Manipal Academy of Higher Education, Manipal, India
MarksMan Healthcare Communications Pvt. Ltd., India
Monash University, Malaysia
Musashino University Institute for Global Affairs (MIGA), Tokyo, Japan
National Center for Child Health and Development, Japan
National Evidence-based Healthcare Collaborating Agency, South Korea
Philippine Health Insurance Corporation
Saw Swee Hock School of Public Health, National University of Singapore, Singapore
Shenyang Pharmaceutical University, China
Sichuan University Chinese Evidence-based Medicine Center, China
Tokyo Metropolitan Government, Tokyo Conventions & Visitors Bureau
Universitas Indonesia, Faculty of Pharmacy, Indonesia
Universitas Padjajaran, Faculty of Pharmacy, Indonesia
University of Pancasila, Faculty of Pharmacy, Indonesia

Conference Sponsors



Your ISPOR Conference App

At your fingertips.

It's easy to personalize and maximize your ISPOR conference experience.



Search: ISPOR

NETWORK: **ISPOR**

WI-FI PASSWORD: **TOKYO2018**



ISPOR Publications

Get published. Get noticed.



ISPOR's family of publications provide ample opportunities to contribute to the science and understanding of health economics and outcomes research (HEOR). Whether you're conducting research for publication in peer-reviewed journals or writing about the everyday use and application of HEOR in healthcare decisions, submitting your research to ISPOR's publications is an excellent way to get noticed and advance the field.



Value in Health is an international, indexed journal that publishes original research and health policy articles that help healthcare leaders make evidence-based decisions.

Value in Health Regional Issues is an online, MEDLINE®-indexed journal that focuses on health-related topics that impact the health systems in the following regions: 1) Asia; 2) Central and Eastern Europe, Western Asia, and Africa; and 3) Latin America.

Value & Outcomes Spotlight is a bimonthly HEOR news magazine that covers timely HEOR topics, updates from ISPOR leadership, and HEOR news from around the world.

505 Lawrence Square Blvd South, Lawrenceville, NJ 08648

© ISPOR - The professional society for health economics and outcomes research

www.ispor.org

Plenary Sessions Featured at ISPOR Asia Pacific 2018



Loh Rijpma



Witookollachit Lou



Lou

FIRST PLENARY SESSION: TRANSFORMING HEALTHCARE AND LEVERAGING DIGITAL HEALTH FOR BETTER HEALTH IN ASIA PACIFIC

Digital disruption impacts every industry, and healthcare is no exception. Digital technologies are transforming the global healthcare landscape and driving healthcare towards better value by improving efficiency and quality and reducing costs. The Asia Pacific region has a highly fragmented healthcare market and its digital transformation is coming into its own. Approaches to digital health in different countries across the region differ widely. The opening plenary will explore how to fully grasp the benefits and potential of digital health: What is the current reality and future of digital health in the region? What are the drivers and barriers for the uptake and deployment of digital health? How can we take digital health to the next level?

Moderator: **Erwin Loh, MBBS, LLB(Hons), MBA, MHSM, PhD**, Executive Director, Innovation, Patient Safety & Experience, and Chief Medical Officer, Monash Health, Melbourne, Australia

Speakers: **Gabe Rijpma**, Senior Director, Health and Social Services, Microsoft Asia, Auckland, New Zealand; **Polawat Witookollachit, MD**, Director, Information Technology and Communication, Ministry of Public Health, Bangkok, Thailand; **Jilan Liu, MD, MHA**, Principal & Consulting Director of Greater China, Joint Commission International, and Vice President & Executive Director of Greater China, Healthcare Information and Management Systems Society, Seattle, WA, USA; **Hwei-Xin Lou, PharmD, MSc (Clinical Pharm)**, Director, Ancillary Care, Integrated Health Information Systems Pte Ltd, and Head, National Pharmacy Program Management Office, Ministry of Health, Singapore



Barefoot Chan



Sun Akazawa

SECOND PLENARY SESSION: REAL-WORLD EVIDENCE IN ASIA PACIFIC: ARE WE READY? IS IT HELPFUL FOR DECISION MAKERS?

Real-world evidence (RWE) is now commonly used to inform drug pricing and reimbursement decisions in Europe and North America. There also are ongoing efforts to incorporate RWE into drug development and regulatory processes in these regions. Recent years have seen an increasing interest in the use of RWE in Asia Pacific. However, the extent that RWE is embraced varies from country to country for many reasons, such as lack of data, poor data quality, data security, and privacy issues. How ready are we for RWE? Where are we now and where are we heading? In this plenary, speakers from various sectors will share their perspectives and valuable insights on the use of RWE, and address barriers impeding its use.

Moderator: **Bart Barefoot**, Director, VEO & Real World Evidence Policy and Advocacy, Value Evidence and Outcomes, Global Medical, GlaxoSmithKline, London, UK

Speakers: **Kinwei Arnold Chan, MD, ScD, FISPE**, Director, Health Data Research Center, National Taiwan University, Director, Department of Medical Research, and Director, Clinical Trial Center, National Taiwan University Hospital, Taipei, Taiwan; **Xin Sun, PhD**, Professor & Director, Chinese Evidence-Based Medicine Center, West China Hospital, Sichuan University, Chengdu, China; **Manabu Akazawa, PhD, MPH**, Professor, Public Health and Epidemiology Department, Meiji Pharmaceutical University, Tokyo, Japan



Mahlich de Somer



Sae Rak Zlateva

THIRD PLENARY SESSION: RISK-SHARING AGREEMENTS: COUNTRY EXPERIENCES, CHALLENGES, AND LESSONS LEARNED

Interest in risk-sharing agreements (RSAs) for innovative therapies is growing due to rising cost pressures, increasing demand for value-based pricing, and uncertainty about the true effectiveness, uptake, and value of the healthcare technology. RSAs are considered as an additional approach to provide access, fairness, and mitigate financial risks to the funders and sponsors. In recent years, the number of RSAs and the number of countries using RSAs have increased significantly. Different countries use different types of RSAs under different banners, such as managed entry or managed access schemes, to solve different healthcare problems. An expert panel will share their experiences and lessons learned in RSAs, and address key issues and practical challenges in implementing these agreements.

Moderator: **Jörg Mahlich, PhD**, Head, Health Economics and Outcomes Research, Janssen Pharmaceutical, and Formal Director, Health Economics in Janssen Japan KK, Neuss, Germany

Speakers: **Elizabeth de Somer**, Chief Executive Officer, Medicines Australia, Canberra, Australia; **Jang Sae Rak**, Deputy Director, Pharmaceutical Listing Division, Pharmaceutical Benefit Department, Health Insurance Review and Assessment Service, Seoul, South Korea; **Gergana Zlateva, PhD**, Vice President, Global Market Access-Oncology, Global Health & Value, Pfizer Inc., New York, NY, USA

ISPOR Asia Pacific 2018

8 – 11 September
Tokyo, Japan

Program & Schedule of Events

● **Saturday** 8 September

Short Courses are training courses offered across 7 HEOR key topic areas. The skill level ranges from introductory to advanced, and continuing education credits are available. Separate registration is required.

● **Sunday** 9 September

Plenary Sessions feature thought-provoking discussions on challenging topics related to healthcare policy, the application of HEOR in healthcare decision making, or methodology.

● **Monday** 10 September

Spotlight Sessions highlight timely topics in HEOR and promote areas of innovation of interest to the ISPOR community.

● **Tuesday** 11 September

Issue Panels (IP) introduce debate with multistakeholder perspectives on new or controversial issues in HEOR.

Workshops (W) discuss new and innovative applications in the conduct and use of HEOR or the latest on real-world data, clinical-, economic-, or patient-reported outcomes, patient-preferences, and healthcare policy.

ISPOR Forums (F) are presented by ISPOR Groups on country/regional health policy, scientific research/initiatives, good practices for outcomes research, research tools, or publications.

Podium Presentations (P) sessions consist of four 15-minute outcomes research presentations on a single topic.

Poster Presentations Sessions contain approximately 200 research posters per session arranged by disease, topic, or healthcare intervention with a scheduled author discussion hour.

Symposia are sponsored presentations related to ISPOR's mission. The sponsor organization selects a subject of interest to delegates and arranges suitable speakers.

Open Meetings for ISPOR Asia Pacific 2018 are organized by the ISPOR Student Network and the ISPOR New Professional Network. These sessions will feature presentations on a wide array of topics that include career advice and scientific related content.

Saturday 8 September

7:00AM-6:00PM REGISTRATION HELP DESK HOURS *Hana Foyer (4th fl)*

8:00AM-12:00PM SHORT COURSE MORNING SESSION

Introduction to Pharmacoeconomics/Health Economics *Akebono Room (47th fl)*
 Track: Economic Methods
 Level: Introductory — This course is designed for those with limited experience with pharmacoeconomics (health economics).
 Faculty: **David B. Matchar, MD**, Duke-NUS Medical School, Singapore, Singapore; **Hong Li, PhD, MPH**, Digital China Health Technologies, Corp., and School of Pharmacy, Cincinnati University, Cincinnati, OH, USA

Introduction to Real-World Data and Informatics in Healthcare *Aozora Room (47th fl)*
 Track: Observational Data Methods
 Level: Introductory — This course is designed for those with little experience with data analysis or observation.
 Faculty: **Jeff J. Guo, PhD**, University of Cincinnati, Cincinnati, OH, USA; **Kinwei Arnold Chan, MD, MPH, ScD**, National Taiwan University, Taipei, Taiwan

Elements of Pharmaceutical/Biotech Pricing I *Ensemble Room (44th fl)*
 Track: Use of Pharmacoeconomic / Economic / Outcomes Research Information
 Level: Introductory — This introductory course is designed for those with limited experience in pharmaceutical pricing and reimbursement.
 Faculty: **Jack M. Mycka**, Medical Marketing Economics LLC, Montclair, NJ, USA; **Manny Papadimitropoulos, PhD**, Eli Lilly, and University of Toronto, Toronto, ON, Canada; **Shanlian Hu, MD, MSc**, Shanghai Health Development Research Center, Shanghai, China

Introduction to Health Technology Assessment (HTA) *Harmony Room (44th fl)*
 Track: Use of Pharmacoeconomic / Economic / Outcomes Research Information
 Level: Introductory — This course is suitable for those with little or no experience with HTA.
 Faculty: **Uwe Siebert, MPH, MSc, ScD, MD**, Harvard Medical School, Institute for Technology Assessment & Department of Radiology, Hall i.T., Austria; **Yen-Huei (Tony) Tarn, PhD, MS**, School of Pharmacy, Kaohsiung Medical University, Kaohsiung, Taiwan

NEW! Budget Impact Analysis I: A 6-Step Approach *Fuji Room (42nd fl)*
 Track: Economic Methods
 Level: Intermediate — This course is designed for those with some experience with pharmacoeconomic analysis.
 Faculty: **C. Daniel Mullins, PhD**, University of Maryland, School of Pharmacy, Baltimore, MD, USA; **Jianwei Xuan, MD, PhD**, Sun Yat-sen University, Guangzhou, China

NEW! Medical Devices in Asia Pacific: Regulatory and Reimbursement Issues *Takao Room (42nd fl)*
 Track: Use of Pharmacoeconomic / Economic / Outcomes Research Information
 Level: Intermediate — This course is designed for those with limited experience in the area of medical device reimbursement and regulatory issues and covers topics within a global context.
 Faculty: **Eugene Salole, PhD, MPH**, Faculty of Medicine, UNSW, Sydney, UK; **Jack Wong, RPh**, Asia Regulatory Professional Association, Singapore

1:00PM-5:00PM SHORT COURSE AFTERNOON SESSION

Introduction to Modeling *Akebono Room (47th fl)*
 Track: Modeling Methods
 Level: Introductory — This course will introduce pharmacoeconomic modeling techniques such as decision analytic modeling, Markov modeling, discrete event models, and other modeling techniques and their appropriate usages with practical application, along with a review of the ISPOR Modeling Good Research Practices.
 Faculty: **Shu Chuen Li, MBA, PhD**, University of Newcastle, Callaghan, NSW, Australia; **Jipan Xie, MD, PhD**, Analysis Group, Inc., New York, NY, USA


Cost Effectiveness Analysis Alongside Clinical Trials *Aozora Room (47th fl)*
 Track: Economic Methods
 Level: Intermediate — Familiarity with economic evaluations will be helpful.
 Faculty: **Chee Jen Chang, PhD**, Chang Gung University, Taoyuan, Taiwan; **David Bin-Chia Wu, PhD**, Janssen Asia Pacific, and Monash University Malaysia, Selangor, Malaysia


Saturday 8 September


Track: Patient-Reported Outcomes Measures (PROMS): Cross-Cultural Development and Validation *Ensemble Room (44th fl)*
Level: Patient-Reported Outcomes Methods
Faculty: Introductory — This course is designed for those with limited experience with quality of life/PRO studies.
Bruce Crawford, MA, MPH, Syneos Health, Tokyo, Japan; **Nan Luo, PhD**, National University of Singapore, Singapore


Track: Retrospective Database Design and Analysis *Harmony Room (44th fl)*
Level: Observational Data Methods
Faculty: Introductory — This course is designed for those with little experience with database analysis.
Jeff J. Guo, PhD, University of Cincinnati, Cincinnati, OH, USA; **Xin Sun, PhD**, West China Hospital of Sichuan University, Chengdu, China

Track: Case Studies in Pharmaceutical / Biotech Pricing II – Advanced *Fuji Room (42nd fl)*
Level: Use of Pharmacoeconomic / Economic / Outcomes Research Information
Faculty: Intermediate — This course is designed for those with limited experience in the area of pharmaceutical pricing and covers topics within a global context.
Jack M. Mycka, Medical Marketing Economics LLC, Montclair, NJ, USA; **Manny Papadimitropoulos, PhD**, Eli Lilly, and University of Toronto, Toronto, ON, Canada; **Shanlian Hu, MD, MSc**, Shanghai Health Development Research Center, Shanghai, China

Track:  **NEW! Budget Impact Analysis II: Applications and Design Issues** *Takao Room (42nd fl)*
Level: Economic Methods
Faculty: Intermediate — This course is designed for those who have basic knowledge of budget impact analyses and desire exposure to these analyses in Excel.
Jianwei Xuan, MD, PhD, Sun Yat-sen University, Guangzhou, China; **Yi Han, PhD, MS, MBA**, WPP Health and Wellness/WG Consulting, New York, NY, USA

5:30PM-6:30PM **EDUCATIONAL SYMPOSIUM** *Grace Room (3rd fl)*
 **Health Technology Assessment of Target Therapy on Colorectal Cancer Treatment**
Sponsored by Merck Serono Co. Ltd.

6:45PM-7:45PM **EDUCATIONAL SYMPOSIUM** *Grace Room (3rd fl)*
 **Benefits and Limitations Underlying the Progress in the Utilization of Real-World Data in Japan**
 The past decade has seen tremendous progress in the use of real-world data (RWD) by outcomes researchers for various purposes in Japan. With this, Japan-specific and non-specific limitations in the use and interpretation of RWD have become evident. In this symposium, leading experts will provide viewpoints on the benefit and limitations of RWD
Sponsored by Pfizer Japan Inc.

8:00PM-9:00PM **EDUCATIONAL SYMPOSIUM** *Grace Room (3rd fl)*
 **Use of HTA in Promoting Innovation in Healthcare in Japan, China, and Taiwan**
 This symposium will provide an update on health technology assessment (HTA) and value framework development in Asia.
Sponsored by MSD

9:00PM-10:30PM **WELCOME RECEPTION** *Eminence Hall (5th fl)*
 The Welcome Reception provides an opportunity to network with colleagues while enjoying a drink, appetizers, and entertainment. Join us for an evening of traditional Japanese experiences. The Tokyo Convention & Visitors Bureau will provide cultural demonstrations. All attendees welcome, no separate registration required.

Sunday 9 September

7:00AM-6:00PM **REGISTRATION HELP DESK HOURS** *Hana Foyer (4th fl)*

8:00AM-12:00PM **SHORT COURSE MORNING SESSION**

 **NEW! Applied Modeling** *Akebono Room (47th fl)*

Track: Modeling Methods
Level: Intermediate — This course is suitable for those who are familiar with the various modeling methods.
Prerequisite: Participation in the ISPOR short course "Introduction to Modeling Methods," or equivalent knowledge, is recommended.
Faculty: **Mark S. Roberts, MD, MPP**, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, USA; **David Bin-Chia Wu, PhD**, Monash University Malaysia, Selangor, Malaysia

Statistical Methods in Health Economic Evaluations *Aozora Room (47th fl)*

Track: Use of Pharmacoeconomic / Economic / Outcomes Research Information
Level: Intermediate — This course is designed for those with a basic understanding of statistics.
Faculty: **Henry A. Glick, PhD**, University of Pennsylvania, Philadelphia, PA; **Chee Jen Chang, PhD**, Chang Gung University, Taoyuan, Taiwan

Health-Related Quality of Life (HRQOL) Weights for Economic Evaluations *Ensemble Room (44th fl)*

Track: Patient Preference Methods
Level: Introductory — No prior knowledge of health-related quality of life is assumed.
Faculty: **Alex Z. Fu, PhD**, Georgetown University, Washington, DC, USA; **Nan Luo, PhD**, National University of Singapore, Singapore

Network Meta-Analysis and Indirect Treatment Comparisons *Harmony Room (44th fl)*

Track: Outcomes Research Methods
Level: Intermediate — This course is designed for those with some understanding of meta-analysis.
Prerequisite: Participation in the short course "Meta-Analysis and Literature Review in Comparative Effectiveness Research," or equivalent knowledge, is recommended.
Faculty: **Jeonghoon Ahn, PhD**, Ewha Womans University, Seoul, South Korea; **Nathorn Chaiyakunapruk, PharmD, PhD**, Monash University, Petaling Jaya, Malaysia

Risk-Sharing/Performance-Based Schemes for Drugs and Medical Devices *Fuji Room (42nd fl)*

Track: Use of Pharmacoeconomic / Economic / Outcomes Research Information
Level: Intermediate — It will be helpful for individuals to be familiar with both the key determinants of pharmaceutical pricing and the main international health systems.
Faculty: **Louis P. Garrison, PhD**, School of Pharmacy University of Washington, Seattle, WA, USA; **Adrian Towse, MA, MPhil**, Office of Health Economics, London, UK

NEW! Introduction to Big Data Analysis: Graph Analytics *Takao Room (42nd fl)*

Track: Observational Data Methods
Level: Intermediate
Faculty: **David R. Holmes III, PhD**, Mayo Clinic College of Medicine, Rochester, MN, USA

12:30PM-7:30PM **RESEARCH POSTER PRESENTATIONS AND EXHIBIT VIEWING - SESSION I** *Hana Ballroom (4th fl)*

1:00PM-1:30PM **WELCOME** *Concord Ballroom (5th fl)*

Welcome from ISPOR CEO/Executive Director
Nancy S. Berg, ISPOR, Lawrenceville, NJ, USA

Welcome from ISPOR President
Federico Augustovski, MD, MSc, PhD, Institute for Clinical Effectiveness and Health Policy (IECS-CONICET), Buenos Aires, Argentina

Conference Program Overview

Conference Co-Chairs: **Takashi Fukuda, PhD**, National Institute of Public Health, Saitama, Japan; **Shinya Saito, MD, PhD**, Okayama University, Tokyo, Japan

Program Committee Co-Chairs: **Shunya Ikeda, MD, MS, DrMedSci**, International University of Health and Welfare, Ohtawara, Japan; **Kun Zhao, MD, PhD, MHSc**, National Health Commission, Beijing, China

Welcome from ISPOR Asia Consortium Executive Committee Chair
Isao Kamae, MD, DrPH, The University of Tokyo, Tokyo, Japan

Sunday 9 September

1:30PM-1:45PM

OPENING SPEECH *Concord Ballroom (5th fl)*

Keynote speaker: **Yashuhiro Suzuki, MPH, MSc, MD, PhD**, Chief Medical & Global Health Officer and Vice-Minister for Health in the Ministry of Health, Labour and Welfare (MHLW), Tokyo, Japan

1:45PM-3:15PM

FIRST PLENARY SESSION *Concord Ballroom (5th fl)*

Transforming Healthcare and Leveraging Digital Health for Better Health in Asia Pacific

Moderator: **Erwin Loh, MBBS, LLB (Hons), MBA, MHSM, PhD**, Executive Director, Innovation, Patient Safety & Experience, and Chief Medical Officer, Monash Health, Melbourne, Australia

Speakers: **Gabe Rijpma**, Senior Director, Health and Social Services, Microsoft Asia, Auckland, New Zealand; **Polawat Witookollachit, MD**, Director, Information Technology and Communication, Ministry of Public Health, Bangkok, Thailand; **Jilan Liu, MD, MHA**, Principal and Consulting Director of Greater China, Joint Commission International, and Vice President & Executive Director of Greater China, Healthcare Information and Management Systems Society, Seattle, USA; **Huei-Xin Lou, PharmD, MSc (Clinical Pharma)**, Director, Ancillary Care, Integrated Health Information Systems Pte Ltd, and Head, National Pharmacy Program Management Office, Ministry of Health, Singapore

3:15PM-3:45PM

BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION I *Hana Ballroom (4th fl)*

3:45PM-4:45PM

BREAKOUT SESSION

IP1: Cost vs Value: What Is the Fair Price of a Drug? *Concord Ballroom A (5th fl)*

Moderator: **Neal Somchand, MSc**, Deallus Consulting, Tokyo, Japan

Panelists: **Mark Sculpher, PhD**, University of York, York, UK; **Takashi Fukuda, PhD**, National Institute of Public Health, Wako, Japan; **Christoph Glaetzer, Dipl. Kfm**, Janssen, Pharmaceutical Companies of Johnson & Johnson, NJ, USA

IP2: Opportunities and Challenges in International Harmonization of HTA of Medical Devices - Gaps Between European and Asian Countries *Concord Ballroom B (5th fl)*

Moderator: **Rosanna Tarricone, MSc, PhD**, Bocconi University, Milano, Italy

Panelists: **Ataru Igarashi, PhD**, The University of Tokyo, Tokyo, Japan; **Sukyeong Kim, PhD, RPh, MPH**, National Evidence-Based Healthcare Collaborating Agency, Seoul, Republic of South Korea

W1: Health Economic Evaluations to Support Public Health Decision-Making in Vaccines: Are Cost-Effectiveness Analysis and Budget Impact Analysis Sufficient to Answer the Policy Questions?

Concord Ballroom C (5th fl)

Discussion Leaders: **Shunya Ikeda, MD**, International University of Health and Welfare, Narita City, Japan; **Nathorn Chaikunapruk, PharmD, PhD**, Naresuan University, Phitsanulok, Thailand; **Baudouin Standaert, MD, PhD**, GSK Vaccines, Wavre, Belgium; **Sharon Zhang, PhD**, GSK Vaccines, Singapore, Singapore

W2: The EQ-5D-5L Instrument: Past, Present and Future *Nishiki Room (4th fl)*

Discussion Leaders: **Kim Rand, PhD**, University of Oslo, Oslo, Norway; **Mark Oppe, PhD**, EuroQol Research Foundation, Rotterdam, The Netherlands; **Nan Luo, PhD**, National University of Singapore, Singapore

P1: Cost Studies *Ohgi Room (4th fl)*

Moderator: **Gordon Liu, PhD**, Peking University National School of Development and PKU China Center for Health Economic Research, Beijing, China

3:45PM-4:00PM

CS1 Factors Impacting Direct Costs of Chronic Kidney Disease Among Chinese Urban Patients in Pre-Dialysis Phase

Liu Y¹, Wang J², Yang L², ¹University of Missouri - Kansas City, Kansas City, MO, USA, ²Peking University, Beijing, China

4:00PM-4:15PM

CS2 Estimation of Life Expectancy, Expected Years of Life Lost, and Lifetime Cost Due to Intracerebral Hemorrhage in Korea

Cheon S¹, Lee H², Jang B², Wang J¹

¹National Cheng Kung University, Tainan, Taiwan, ²Kyung Hee University, Seoul, Republic of South Korea

4:15PM-4:30PM

CS3 Direct Medical Costs Associated with Cardiovascular Diseases Among the HIV-Infected Patients in Taiwan: A Population-Based Study

Liao C¹, Yang C², Chen P², Ou H², Toh HS¹, Chen Z³, Ko N², ¹Chimei Medical Center, Tainan City, Taiwan, ²National Cheng Kung University, Tainan City, Taiwan, ³Chimei Medical Center, Tainan, Taiwan

4:30PM-4:45PM

CS4 Healthcare Resource Utilization and Economic Burden of Herpes Zoster in Japanese Patients with Immunocompromised Conditions: A Claims Database Cohort Study

Imafuku S¹, Mizukami A², Goto Y³, Ito C⁴, Curran D⁵, Holl K², Matsuki T²

¹Fukuoka University School of Medicine, Fukuoka, Japan, ²GSK, Tokyo, Japan, ³National Cancer Center Hospital, Tokyo, Japan, ⁴Japan Medical Data Center Co., Ltd., Tokyo, Japan, ⁵GSK, Wavre, Belgium

Sunday 9 September

P2: Cardiovascular and Diabetes Studies *Grace Room (3rd fl)*

Moderator: Shan Lian Hu, MS, MD, Shanghai Health Development Research Center, Shanghai, China

3:45PM-4:00PM

CV1 Trends in Medication Utilization, Glycemic Control, Rates of Severe Hypoglycemia and Lower Limb Amputations Among Type 2 Diabetes Patients with Chronic Kidney Disease in Singapore from 2012 to 2017
Cheeh MH, Tan YZ, Lim PS, Khee GY, Thumboo J, Goh S, Bee YM, Singapore General Hospital, Singapore, Singapore

4:00PM-4:15PM

CV2 Identification of Low-Risk Stable Cardiovascular Patients and Patient Acceptance for Fast-Track Medication Refill Service

Lee VW¹, Kwan WH¹, Ko XC¹, Yan BP², ¹The Chinese University of Hong Kong, Shatin, Hong Kong, ²The Chinese University of Hong Kong, Hong Kong

4:15PM-4:30PM

CV3 The Prevalence and Burden of Hypertension and Obesity Among Patients with Type 2 Diabetes in Japan
Carpinella CM¹, Sternbach N², Doane MJ³, Fukuda T⁴, Chen Y⁵, **Stankus AP⁶**, ¹Kantar Health, San Mateo, CA, USA, ²Kantar Health, New York City, NY, USA, ³Kantar Health, Horsham, PA, USA, ⁴National Institute of Public Health, Wako, Japan, ⁵Kantar Health, Singapore, Singapore, ⁶Kantar Health, New York, NY, USA

4:30PM-4:45PM

CV4 Cost-Effectiveness Analysis of Acute Ischemic Stroke Treatment According to Comorbidity Index
Han E, Yonsei University, Incheon, Republic of South Korea

4:45PM-5:00PM

BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION I *Hana Ballroom (4th fl)*

5:00PM-6:00PM

BREAKOUT SESSION

IP3: How Will Patient Centricity Be Captured in the Japanese HTA and Healthcare Reform? *Concord Ballroom A (5th fl)*

Moderator: Adrian Towse, MA, MPhil, Office of Health Economics, London, UK

Panelists: Shunya Ikeda, MD, International University of Health and Welfare, Narita City, Japan; Makoto Kobayashi, PhD, MEng, CRECON Medical Assessment Inc., Tokyo, Japan; Durhane Wong-Rieger, PhD, MA, Canadian Organization for Rare Disorders, Toronto, ON, Canada

IP4: Global Alignment on Approaches to Use of Real-World Evidence in Decision Making *Concord Ballroom B (5th fl)*

Moderator: Rob Thwaites, MA, MCom, Takeda, London, UK

Panelists: Nicholas Crabb, PhD, NICE, Manchester, UK; Shunichi Fukuhara, MD, PhD, Kyoto University, Kyoto, Japan; David Pearce, BPharm, MSc, Takeda Pharmaceuticals, Singapore, Singapore

IP5: Better the Devil You Know? QALYs and Their Alternatives in Drug Reimbursement Decision-Making *Concord Ballroom C (5th fl)*

Moderator: Hansoo Kim, MSc, Monash University, Melbourne, Australia

Panelists: Mark Sculpher, PhD, University of York, York, UK; J. Jaime Caro, MDCM, McGill University, Montreal, QC, Canada; Danny Liew, PhD, MBBS, Monash University, Melbourne, Australia

W3: Generating and Communicating HEOR Evidence to Demonstrate Pharmaceutical Products' Value: Recommendations for Chinese Payers on Evidence Submission Guidelines *Nishiki Room (4th fl)*

Discussion Leaders: Xin (Cindy) Gao, PhD, Pharmerit International, Bethesda, MD, USA; Rong Shao, PhD, China Pharmaceutical University, Nanjing, China; Shanlian Hu, MD, MSc, Shanghai Health Development Research Center, Shanghai, China

5:00PM-5:15PM

P3: Health Technology Assessment Studies *Ohgi Room (4th fl)*

HT1 International Comparison of HTA Decisions for Oncology Products

Dabbous M¹, Achour L², Chachoua L³, Hanna E⁴, Toumi M¹, ¹Aix Marseille University, Marseille, France, ²Paris Dauphine University, Paris, France, ³Market Access Society, Paris, France, ⁴Creativ-Ceutical, Paris, France

5:15PM-5:30PM

HT2 The Introduction of Health Technology Assessment in Japan: Lessons Learned from Three Other New HTA Markets (Brazil, Poland and South Korea)

Escafit M¹, Foy C¹, **Paglia R²**, ¹Consulting at McCann Health, London, UK, ²Consulting at McCann Health, New York, NY, USA

5:30PM-5:45PM

HT3 An Exploration of Pharmacoeconomic Publication Trends in Japan, Singapore and China Between 2000-2018

Wickstead RM¹, Tomlinson P¹, van Hest N¹, Steeves S², Miah F¹, Painter C¹, Uchea C¹, ¹Costello Medical, London, UK, ²Costello Medical, Cambridge, UK

5:45PM-6:00PM

HT4 Clinical Effectiveness and Cost-Effectiveness of Sugammadex for Reversal of Neuromuscular Block: A Rapid Health Technology Assessment

Men P¹, Gu X¹, Zhang H², Zhai S¹, ¹Department of Pharmacy, Peking University Third Hospital, Beijing, China, ²MSD China Holding Co. Ltd., Shanghai, China

Sunday 9 September

P4: Pricing Studies *Grace Room (3rd fl)*

Moderator: **Qiang Sun, PhD**, Shandong University, Shandong, China

5:00PM-5:15PM

PR1 Value-Based Pricing in Singapore: Is It a Race to the Bottom?

Ghosh W, Bose R, Viswambaram A, Brooks-Rooney C, Costello Medical Singapore Pte Ltd, Singapore, Singapore

5:15PM-5:30PM

PR2 The Impact of Generic Drug Entry on Market Shares and Prices of Brand-Name Drugs – Evidence from Chinese Pharmaceutical Market

Chen J, Tian Y, Shi LW, School of Pharmaceutical Sciences, Peking University, Beijing, China

5:30PM-5:45PM

PR3 Drivers of High Drug Prices in Japan, a Preliminary Research

Ueyama M¹, Fukushima A², Oku Y³, Dorey J², Onishi Y⁴, François C², Toumi M⁵, ¹Creativ-Ceutical K.K., Tokyo, Japan, ²Creativ-Ceutical, Paris, France, ³Kyoto University, Kyoto, Japan, ⁴Creativ-Ceutical, Tokyo, Japan, ⁵Aix-Marseille University, Marseille, France

5:45PM-6:00PM

PR4 A Study on Factors Influencing Drug Prices Among National Public Hospitals in the Philippines

Apostol GL, Epimetrics, Inc., Quezon City, Philippines

5:00PM-6:00PM

ISPOR STUDENT CAREER EVENT – HOW I GOT HERE (*Open to all students*) *Ensemble (44th fl)*

Students are invited to the first ever Student Network event at an ISPOR Asia Pacific Conference! Hear from HEOR professionals who will provide input on their career path and tips for those interested in a career in academia, government/HTA, or industry.

6:00PM-7:30PM

EXHIBITORS' RECEPTION & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION I *Hana Ballroom (4th fl)*

6:15PM-7:15PM

SPOTLIGHT SESSION *Concord Ballroom A (5th fl)*

Updates and Outlook on Japan's National HTA Pilot Program

As the Japanese government currently undertakes an extensive pilot program to determine the outlook for national HTA, this session will provide an inside look on the key issues being discussed and outcomes after the program's conclusion in April 2019.

6:30PM-7:30PM

RESEARCH POSTER AUTHOR DISCUSSION HOUR - SESSION I *Hana Ballroom (4th fl)*

7:30PM-9:00PM

ASIA CONSORTIUM RECEPTION *Eminence Hall (5th fl)*

Learn. Apply. Advance.



Learn from globally renowned leaders.
Apply knowledge to improve research methodologies.
Advance the science; advance your career.

Don't miss this opportunity to register for the premier educational program in health economics and outcomes research (HEOR). The ISPOR Short Course program offers engaging coursework—ranging from introductory to advanced—and hands-on learning to enhance attendees' knowledge and skills.

Key advantages of ISPOR's Short Course programs:

- Learn from global leaders in the field of HEOR
- Develop your knowledge and skills through engaging coursework
- Review the latest research on best practices and best methods in HEOR
- Gain hands-on experience that translates into immediate, practical application
- Earn up to 16 CPE or CME credits (available at select conferences)

Upcoming conference locations: Tokyo 2018; New Orleans 2019; Bogota 2019; Copenhagen 2019
©2018 ISPOR – The professional society for health economics and outcomes research

**Come for the courses—
stay for the conference!**

Reserve your seat in the class today.

Register for the Short Course program at
www.ispor.org



Monday 10 September

7:00AM-6:00PM **REGISTRATION HELP DESK HOURS** Hana Foyer (4th fl)

7:15AM-8:15AM **EDUCATIONAL SYMPOSIUM** Nishiki Room (4th fl)



Challenges and Opportunities in Health Technology Assessment Development in China

Health technology assessment (HTA) has been evolving rapidly in China; however, its development has faced many challenges. In this symposium, attendees will be introduced to common methodological challenges. The presenters will discuss potential approaches for addressing the challenges, as well as opportunities for HTA development in China. Sponsored by Analysis Group

8:30AM-10:00AM **WELCOME & SECOND PLENARY SESSION** Concord Ballroom (5th fl)

Welcome from ISPOR Asia Consortium Executive Committee Chair

Isao Kamae, MD, DrPH, The University of Tokyo, Tokyo, Japan

Second Plenary Session: Real-World Evidence in Asia Pacific: Are We Ready? Is It Helpful for Decision Makers?

Moderator: **Bart Barefoot**, Director, VEO and Real-World Evidence Policy and Advocacy, Value Evidence and Outcomes, Global Medical, GlaxoSmithKline, London, UK

Speakers: **Kinwei Arnold Chan, MD, ScD, FISPE**, Director, Health Data Research Center, National Taiwan University, Director, Department of Medical Research, and Director, Clinical Trial Center, National Taiwan University Hospital, Taipei, Taiwan; **Xin Sun, PhD**, Professor, Chinese Evidence-Based Medicine Center, West China Hospital, Sichuan University, Chengdu, China; **Manabu Akazawa, PhD, MPH**, Professor, Public Health and Epidemiology Department, Meiji Pharmaceutical University, Tokyo, Japan

8:30AM-1:30PM **RESEARCH POSTER PRESENTATIONS - SESSION II** Hana Ballroom (4th fl)

10:00AM-10:30AM **BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION II** Hana Ballroom (4th fl)

10:30AM-11:30AM **BREAKOUT SESSION**

IP6: What Is the HTA Implication in Patient Access and What Are the Critical Factors to Make a Balance for Innovative Medicines? – 10 Years Experience with HTA in Korea Concord Ballroom A (5th fl)

Moderator: **Eui-Kyung Lee, PhD**, School of Pharmacy, Sungkyunkwan University, Suwon, Republic of South Korea

Panelists: **Sungju Kim, PhD**, Novartis Korea, Seoul, Republic of South Korea; **Jang Sae Rak**, Deputy Director, Pharmaceutical Listing Division, Pharmaceutical Benefit Department, Health Insurance Review and Assessment Service, Seoul, South Korea; **Cammy Yeun, PhD**, Abbvie JAPAC, Tokyo, Japan

IP7: What Is the Value of Rare Disease Therapies for Developing Healthcare Systems? Concord Ballroom B (5th fl)

Moderator: **Ran Geng, BSE**, Venture Capital, Beijing, China

Panelists: **Gordon G Liu, PhD**, National School of Development, Peking University, Beijing, China; **Kevin Huang**, China Organization for Rare Disorders, Beijing, China; **Thomas Butt, PhD**, Peking University and University College London, Beijing, China

W4: The New Wave in Real-World Evidence - Integrated Datasets Concord Ballroom C (5th fl)

Discussion Leaders: **Tom Haskell, BS**, Kantar Health, Horsham, PA, USA; **Ataru Igarashi, PhD**, University of Tokyo, Graduate School of Pharmaceutical Sciences, Tokyo, Japan; **Yuji Yamamoto, MD, MBA**, MinaCare Co. Ltd., Tokyo, Japan; **Vince Grillo, MBA, PhD**, Kantar Health, Singapore, Singapore

W5: Japanese HTA and Pricing: Current Methods and Future Potential Nishiki Room (4th fl)

Discussion Leaders: **Isao Kamae, MD, DrPH**, The University of Tokyo, Graduate School of Public Policy, Tokyo, Japan; **Makoto Kobayashi, PhD, MEng**, CRECON Medical Assessment Inc., Tokyo, Japan; **Parashar Patel, MPA**, Boston Scientific Corporation, Marlborough, MA, USA; **Peter J. Neumann, ScD**, Tufts Medical Center, Boston, MA, USA

P5: Cancer Studies Ohgi Room (4th fl)

Moderator: **Haitham Tuffaha, BPharm, MBA, MSc, PhD**, Griffith University, Brisbane, Australia

10:30AM-10:45AM **CN1 The Economic Impact of Switching to Trastuzumab Biosimilar for the Treatment of Metastatic Breast Cancer from a Chinese Payer Perspective**

Liu S, Bozkaya D, Brown D, Xcenda, LLC, Palm Harbor, FL, USA

10:45AM-11:00AM **CN2 Cross-Country Comparison of Cancer-Specific Multi-Attribute Utility Instruments: Relative Weighting and Ranking of Health-Related Quality of Life Domains in Country-Specific Utility Algorithms**

King MT¹, Norman R², Kemmler G³, McTaggart-Cowan H⁴, Rowen D⁵, Pickard AS⁶, Viney R⁷, ¹University of Sydney, Sydney,

Monday 10 September

- Australia, ²Curtin University, Perth, Australia, ³Medical University of Innsbruck, Innsbruck, Austria, ⁴Canadian Centre for Applied Research in Cancer Control, Vancouver, BC, Canada, ⁵University of Sheffield, Sheffield, UK, ⁶University of Illinois at Chicago, Chicago, IL, USA, ⁷University of Technology, Sydney, Sydney, Australia
- 11:00AM-11:15AM **CN3 Cost Effectiveness Analysis of Using a Novel Diagnostic Test in Gastric Cancer Screening Programs for Population at Intermediate and High Risk**
Kapoor R¹, Feng Z², So J³, Zou R⁴, Zhou L⁴, Too H², Yeoh KG², Yik-Ying T¹, Yoong JS², ¹National University of Singapore, Singapore, ²National University of Singapore, Singapore, ³National University Hospital, Singapore, Singapore, ⁴Mirxes, Singapore, Singapore
- 11:15AM-11:30AM **CN4 Economic Burden of Lung Cancer Attributable to Smoking in China in 2015**
Shi J¹, Liu C², Ren J¹, Huang H¹, Wang L³, Parascandola M⁴, Wu N⁵, Zou X⁶, Liu G⁷, He J¹, Dai M¹, ¹Program Office for Cancer Screening in Urban China, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ²Office of Cancer Early Diagnosis and Early Treatment, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ³National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ⁴National Cancer Institute, Bethesda, MD, USA, ⁵National Cancer Center / Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ⁶National Office for Cancer Prevention and Control, National Cancer Center / Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ⁷School of Health Management, Harbin Medical University, Heilongjiang, China
-
- P6: Medical Device and Diagnostics Studies** *Grace Room (3rd fl)*
 Moderator: **Kenneth K. C. Lee, MPhil, PhD**, Monash University Malaysia, Selangor, Malaysia
- 10:30AM-10:45AM **MD1 Sudden Cardiac Death After Revascularization in Patients with Coronary Artery Disease and Left Ventricular Dysfunction**
Wang S¹, Borah BJ², Dunlay SM², Chamberlain A², Liu J¹, ¹Beijing Anzhen Hospital, Beijing, China, ²Mayo Clinic College of Medicine, Rochester, MN, USA
- 10:45AM-11:00AM **MD2 Economic Analysis of Urea-Excipient Drug-Coated Balloon Therapy for Treatment of Femoropopliteal Artery Disease in Japan**
 Pietzsch JB¹, Garner AM¹, Hosotani M², Manda B³, **Geisler BP¹**, Yokoi H⁴, ¹Wing Tech Inc., Menlo Park, CA, USA, ²Medtronic Japan, Tokyo, Japan, ³Medtronic Cardiovascular, Santa Rosa, CA, USA, ⁴Fukuoka Sanno Hospital, Fukuoka, Japan
- 11:00AM-11:15AM **MD3 Cost-Effectiveness Analysis of Mechanical Thrombectomy with ReVive SE® vs Intravenous Thrombolysis for the Treatment of Acute Ischemic Stroke in China**
 Jia Y¹, Liu J², Yang P², Zhang Y², Zhang Y², Li Z², **Zhang L³**, Lin Z³, Tan J³, Xuan J⁴, ¹Johnson & Johnson Medical (China) Ltd., Shanghai, China, ²Changhai Hospital, Shanghai, China, ³Shanghai Centennial Scientific Co. Ltd., Shanghai, China, ⁴Health Economic Research Institute, School of Pharmacy, Sun Yat-Sen University, Guangzhou, China
- 11:15AM-11:30AM **MD4 Validation of the Malay Version of Mini-Addenbrooke's Cognitive Examination: A Pilot Study**
Hammad MA¹, Syed Sulaiman SA¹, Aziz NA², Sha'aban A¹, Saeed M¹, Mohamed Noor DA¹
¹Universiti Sains Malaysia, Penang, Malaysia, ²Penang General Hospital, Penang, Malaysia
-
- 11:30AM-2:30PM **LUNCH, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION II** *Hana Ballroom (4th fl)*
-
- 12:00PM-1:00PM **EDUCATIONAL SYMPOSIUM** *Nishiki Room (4th fl)*

Appraisal and Assessment with an Emphasis on Patient Advocacy
 The objective of this symposium is to share the experience and importance of different health technology assessment (HTA) bodies with patient advocates on the committee, their role, and how it has made a positive impact on the decision making of these bodies.
 Sponsored by *Eli Lilly & Company*
-
- 12:30PM-1:30PM **RESEARCH POSTER AUTHOR DISCUSSION HOUR - SESSION II** *Hana Ballroom (4th fl)*
-
- 1:15PM-2:15PM **EDUCATIONAL SYMPOSIUM** *Nishiki Room (4th fl)*

Evaluations on the Health Technology Assessment Era in Japan – From Governmental, Academic, and Pharmaceutical Perspectives
 Using cost-effectiveness analysis as a key evaluation, a health technology assessment system has been piloted in Japan during the past few years and will be fully implemented soon. Invited speakers from the advisory committee to the Japanese government, academia, and the pharmaceutical industry will share views on the experience and outlook of HTA in Japan.
 Sponsored by *Otsuka Pharmaceutical Co., Ltd.*

Monday 10 September

2:30PM-3:30PM

SPOTLIGHT SESSION

IP8: Global Horizon Scanning: Policy Implications and Practicalities *Concord Ballroom A (5th fl)*

Introducer: **Isao Kamae, MD, DrPH**, Professor of Health Technology Assessment and Public Policy, Graduate School of Public Policy, The University of Tokyo, Tokyo, Japan

Moderator: **Karen Facey**, Senior Research Fellow, University of Edinburgh, Usher Institute of Population Health Sciences and Informatics, Edinburgh, UK

Panelists: **Sukyeong Kim, PhD**, Director, Coordinating Center for National Health Clinical Research in National Evidence-Based Healthcare Collaborating Agency (NECA), Seoul, South Korea; **Franz Pichler, PhD**, Senior Director, Global Public Policy, Eli Lilly, Sydney, Australia; **Kun Zhao, MD, PhD, MHSc**, Professor & Director, Division of Health Policy Evaluation and Technology Assessment, China National Health Development Research Center, National Health Commission, Beijing, China

W6: Response-Based Cost-Effectiveness Modeling in Immuno-Oncology *Concord Ballroom B (5th fl)*

Discussion Leaders: **J. Jaime Caro, MDCM**, McGill University, Montreal, QC, Canada; **Noemi Muszbek, MSc**, Evidera, London, UK; **Joe Zhuo, PhD**, Merck KGaA, Billerica, MA, USA

W7: How Can HTA Methods Be Adapted to Meet the Special Characteristics of Medical Devices?

Concord Ballroom C (5th fl)

Discussion Leaders: **Rosanna Tarricone, MSc, PhD**, Bocconi University, Milano, Italy; **Michael F. Drummond, MCom, DPhil**, University of York, York, UK; **Rei Goto, MD, PhD**, Keio University, Yokohama, Japan

2:30PM-7:30PM

RESEARCH POSTER PRESENTATIONS - SESSION III *Hana Ballroom (4th fl)*

3:45PM-4:45PM

BREAKOUT SESSION

IP9: A Real-World Data (RWD) Roadmap in China: Challenges and Opportunities for In Vitro Diagnostics

Concord Ballroom A (5th fl)

Moderator: **Meng Chun Gong, MD**, National Rare Diseases Registry System of China, Beijing, China

Panelists: **Si Yan Zhan, PhD**, Peking University, Beijing, China; **Yan Xiao, MD, PhD**, Roche Diagnostics, Pleasanton, CA, USA; **Xiao Qing Liu, MD**, Peking Union Medical College Hospital, Beijing, China

IP10: What Evidence Should Be Used to Quantify Cost-Effectiveness Thresholds for Decision-Making in the Asia Pacific Region? *Concord Ballroom B (5th fl)*

Moderator: **Ryota Nakamura, PhD**, Hitotsubashi University, Tokyo, Japan

Panelists: **Mark Sculpher, PhD**, University of York, York, UK; **Yot Teerawattananon, PhD**, Health Intervention and Technology Assessment Program, Muang, Nonthaburi, Thailand; **Jonathan Karnon, PhD**, The University of Adelaide, Adelaide, Australia

W8: From Data Science to Decision Science in Health Technology Assessment: A Case of Oncology

Concord Ballroom C (5th fl)

Discussion Leaders: **Jittrakul Leartsakulpanitch, PhD**, Janssen Asia Pacific, Singapore, Singapore; **Bruce Crawford, MPH, MA**, Syneos Health, Tokyo, Japan; **Eui-Kyung Lee, PhD**, School of Pharmacy, Sungkyunkwan University, Suwon, Republic of South Korea; **Kenshi Suzuki, MD, PhD**, Department of Myeloma Amyloidosis Center, Japanese Red Cross Medical Center, Tokyo, Japan

W9: Bridging the Gap Between Efficacy and Effectiveness: Using Both Real-world and Trial-based Evidence to Improve Clinical Decision Making *Nishiki Room (4th fl)*

Discussion Leaders: **Fei-Yuan Sharon Hsiao**, Associate Professor, National Taiwan University; **Bor-Sheng Ko**, Attending Physician and Clinical Assistant Professor, National Taiwan University Hospital; **Ming-Hui Tai**, Amgen; Han-I Wang, Research fellow, University of York

W10: Treatment Patterns Using Administrative Claims Data: Guiding Principles for Imperfect Data

Ohgi Room (4th fl)

Discussion Leaders: **Steve Sherman, MPH**, Creativ-Ceutical, Chicago, IL, USA; **Kenji Adachi, PhD**, Amgen Astellas BioPharma K.K., Chiyoda-ku, Tokyo, Japan; **Yoshie Onishi, DrPH, MS, MPH, RPh**, Creativ-Ceutical K.K., Tokyo, Japan; **Samuel Aballea, PhD**, Creativ-Ceutical, Paris, France

P7: Infectious Disease Studies *Grace Room (3rd fl)*

Moderator: **Paul Scuffham, PhD**, Griffith University and Menzies Health Institute, Queensland, Australia

3:45PM-4:00PM

IN1 Impact of Sofosbuvir-Based Regimens for Chronic Hepatitis C Infection: A Work Productivity Model from Mainland China

Ye X¹, Xu X², Xie Q³, Tang H⁴, **Xuan J⁵**, ¹The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China, ²Department of Infectious Diseases, Peking University First Hospital, Beijing, China, ³Shanghai Jiaotong University School of Medicine, Shanghai, China, ⁴West China Hospital of Sichuan, Chengdu, China, ⁵Health Economic Research Institute, School of Pharmacy, Sun Yat-Sen University, Guangzhou, China

Monday 10 September

- 4:00PM-4:15PM **IN2 Trends of Prescription Pattern in Pediatric Intensive Care Unit: An Observational Study**
Magaji BS¹, Ashwin B¹, Saraswathy GR¹, Krishna Murthy M², Ramya R¹, ¹M S Ramaiah University of Applied Sciences, Bangalore, India, ²Ramaiah University of Applied Sciences, Bangalore, India
- 4:15PM-4:30PM **IN3 How Much Do Malaysians Value Dengue Vaccine? Evaluating the Willingness to Pay for Hypothetical Dengue Vaccine with Two-Part Model**
Yeo HY¹, Shafie AA², ¹Clinical Research Center, Hospital Seberang Jaya, Seberang Jaya, Penang, Malaysia, ²Universiti Sains Malaysia, Penang, Malaysia
- 4:30PM-4:45PM **IN4 The Public Health Impact and Cost-Effectiveness of School-Based Nine-Valent Human Papillomavirus Female Vaccination Compared with Bi-Valent and Quadrivalent Vaccination in Malaysia**
 Woo Y¹, **Hsu T²**, Pavelyev A³, LeVan R³, Prabhu VS³, ¹University of Malaya, Kuala Lumpur, Malaysia, ²MSD Pharma (Singapore) Pte. Ltd, Singapore, Singapore, ³Merck & Co., Inc., Kenilworth, NJ, USA
-
- 4:45PM-5:00PM **BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION II** *Hana Ballroom (4th fl)*
-
- 5:00PM-6:00PM **BREAKOUT SESSION**
- IP11: A Trial HTA Introduction in Japan: Learning and Way Forward** *Concord Ballroom A (5th fl)*
Moderator: Wonjoo Jung, MPharm, Janssen, Tokyo, Japan
Panelists: Takashi Fukuda, PhD, National Institute of Public Health, Wako, Japan; Ataru Igarashi, PhD, The University of Tokyo, Tokyo, Japan; Christopher Hourigan, MBA, PhRMA, Tokyo, Japan
- IP12: How to Measure and Value Health Benefits to Facilitate Priority Setting for Pediatric Population: Development and Application Issues** *Concord Ballroom B (5th fl)*
Moderator: Gang Chen, PhD, MSc, Monash University, Melbourne, Australia
Panelists: Nan Luo, PhD, National University of Singapore, Singapore; Ruoyan Gai, PhD, National Center for Child Health and Development of Japan, Tokyo, Japan
- W11: Value of Innovative Medications from the Patients' Perspective in Asia** *Concord Ballroom C (5th fl)*
Discussion Leaders: Gordon G Liu, PhD, National School of Development, Peking University, Beijing, China; Hae Sun Suh, PhD, MPharm, MA, Pusan National University, Busan, Republic of South Korea; Jasmine Pwu, PhD, MOHW, Taipei, Taiwan; Rei Goto, MD, PhD, Keio University, Yokohama, Japan
- W12: Dragon's Offer: Risk Sharing for Early Access to Innovation in China** *Nishiki Room (4th fl)*
Discussion Leaders: Sandeep Duttgupta, PhD, CBPartners, New York, NY, USA; Junfeng Ding, MSc, Taikang Group Online Health Service, Beijing, China; Qiao Gong, BSc, Taikang Group Online Health Service, Beijing, China; Jun Li, PhD, RDPAC, Beijing, China
-
- P8: Medication Adherence Studies** *Ohgi Room (4th fl)*
Moderator: Ming Hu, PhD, West China School of Pharmacy, Sichuan University, Chengdu, China
- 5:00PM-5:15PM **AD1 Adherence to Insulin in Singaporean Pediatric Type 1 Diabetes Patients and Its Association with Glycemic Control and Healthcare Utilization**
Chua B¹, Lim XY¹, Poh KM¹, Stephanie J¹, Cheen M², Lim ST¹, Lek N¹, ¹KK Women's and Children's Hospital, Singapore, Singapore, ²Singapore General Hospital, Singapore, Singapore
- 5:15PM-5:30PM **AD2 Assessment of Patient Compliance, Its Associated Factors and Predictable Interventions**
 Butt H¹, **Muzaffar Z²**, Rasool F², Mohsin M², ¹Islamia University Bahawalpur, Multan, Pakistan, ²Bahauddin Zakriya University, Multan, Pakistan
- 5:30PM-5:45PM **AD3 Comparison of Persistence and Adherence Between Fixed-Dose Combination Therapy and Two-Pill Combination Therapy in Japanese Patients with Type 2 Diabetes Mellitus Using Two Administrative Databases**
Oh A¹, Katou H¹, Kisanuki K¹, Onishi Y², Guelfucci F³, Amri I⁴, Argoubi R⁴, Shimasaki Y¹, Nishimura R⁵, ¹Takeda Pharmaceutical Company Ltd., Tokyo, Japan, ²Creativ-Ceutical K.K., Tokyo, Japan, ³Creativ-Ceutical, Paris, France, ⁴Creativ-Ceutical, Tunis, Tunisia, ⁵Jikei University School of Medicine, Tokyo, Japan
- 5:45PM-6:00PM **AD4 Incorporating Adherence in Cost-Effectiveness Analyses of Interventions for Asthma Treatment: A Systematic Review**
Chongmelaxme B¹, Chaiyakunapruk N², Dilokthornsakul P¹, ¹Naresuan University, Phitsanulok, Thailand, ²Monash University, Petaling Jaya, Malaysia
-
- P9: Modeling Methods** *Grace Room (3rd fl)*
Moderator: Chee Jen (CJ) Chang, PhD, Chang Gung University, Taoyuan, Taiwan
- 5:00PM-5:15PM **MO1 Extrapolation of Individual Survival Curves: What Can We Learn from Registry Data?**
Gray J¹, Sullivan T¹, Sorich M², Salter A¹, Karnon J¹, ¹The University of Adelaide, Adelaide, Australia, ²Flinders University, Bedford Park, Australia

Monday 10 September

- 5:15PM-5:30PM **MO2 How Errors in the Implementation of Background Mortality Leads to Bias in Models**
Bullement A¹, Hatswell AJ², ¹BresMed Health Solutions, Sheffield, UK, ²Delta Hat Limited and University College of London, Nottingham, UK
- 5:30PM-5:45PM **MO3 Towards a More Accurate Budget Impact Analysis: Population-Level Screening for Hepatitis C Virus in Ontario, Canada**
Wong WW¹, Hamadeh A¹, Haines A², Feng Z³, Krahn M², ¹University of Waterloo, Kitchener, ON, Canada, ²Toronto Health Economics and Technology Assessment Collaborative, Toronto, ON, Canada, ³University of Guelph, Guelph, ON, Canada
- 5:45PM-6:00PM **MO4 Assessing the Appropriateness of Existing Model Adaptation Methods for Low and Middle-Income Countries**
 Alshreef A¹, Macquilkan K², Dawkins B³, Riddin J⁴, Ward S¹, Meads D³, **Taylor M⁵**, Dixon S¹, Culyer T⁶, Hofman K⁷, Ruiz F⁸, Chalkidou K⁸, Lord J⁹, Edoka I², ¹University of Sheffield, Sheffield, UK, ²University of Witwatersrand, Jo, South Africa, ³University of Leeds, Leeds, UK, ⁴National Department of Health, Pretoria, South Africa, ⁵York Health Economics Consortium, University of York, York, UK, ⁶University of York, York, UK, ⁷Wits School of Public Health, Johannesburg, South Africa, ⁸Imperial College London, London, UK, ⁹University of Southampton, Southampton, UK

6:00PM-7:30PM **EXHIBITORS' RECEPTION & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION III** *Hana Ballroom (4th fl)*

6:15PM-7:15PM **BREAKOUT SESSION**

F1: Understanding the Evolving Healthcare Landscape in Asia Pacific: Real-World Data and HTA
Concord Ballroom A (5th fl)

Asia Consortium Health Technology Producers (Industry) Committee

Moderator: Ramon Lyu, MS, Johnson & Johnson Medical (China) Ltd., Shanghai, China

Speakers: Jianwei Xuan, MD, PhD, Sun Yat-sen University, Guangzhou, China; **Sang-Soo Lee, PhD, MBA**, Medtronic Korea, Ltd., Seoul, Republic of South Korea; **Ruoyan Gai, PhD**, National Center for Child Health and Development of Japan, Tokyo, Japan; **Bruce C.M. Wang, PhD**, Elysia Group, LLC, New York, NY, USA

F2: Health Technology Assessment of Medical Devices in Asia Pacific *Concord Ballroom B (5th fl)*

Asia Consortium Health Technology Assessment Agencies, Healthcare Policymakers & Payers Committee

Moderator: Devarshi Bhattacharyya, MSc, MPH, Assistant Director, Kalam Institute of Health Technology (KIHT), Visakhapatnam, India

Speakers: Wudong Guo, PhD, China National Health Development Research Center, National Health Commission, Beijing, China; **Richard J Milne, MSc, PhD**, University of Auckland, Auckland, New Zealand; **Alexander Kostyuk, MD, PhD**, Ministry of Health and Social Development, Astana, Kazakhstan; **Sukyeong Kim, PhD, RPh, MPH**, National Evidence-Based Healthcare Collaborating Agency, Seoul, Republic of South Korea

F3: ISPOR Scientific and Health Policy Groups *Concord Ballroom C (5th fl)*

This session will provide an overview of ISPOR's numerous Scientific and Health Policy Groups that advance health economics and outcomes research and its use in healthcare decisions. These groups consist of Special Interest Groups, Good Practices for Outcomes Research Task Forces, Special Task Forces, and Council Working Groups. Presenters will share the mission and objectives of each group, their current projects, and will explain how ISPOR members can become involved.

Speakers: Clarissa Cooblall, Manager, Scientific and Health Policy Initiatives, ISPOR; **Lucinda Orsini**, Associate Chief Science Officer, ISPOR

6:30PM-7:30PM **RESEARCH POSTER AUTHOR DISCUSSION HOUR - SESSION III** *Hana Ballroom (4th fl)*

HEOR Career Center Advance Your Career...

...with ISPOR's HEOR Career Center—the job site for professionals in health economics and outcomes research (HEOR). The HEOR Career Center is the only job site dedicated to careers in the field that is powered by the leading global professional society in HEOR.

Job Candidates:

Jump-start your career with ISPOR's HEOR Career Center

- Free and confidential resume posting
- Automatic email notifications
- Access to job seeker resources

Employers:

Posting with the ISPOR HEOR Career Center offers access to professionals in the leading society focused on health economics and outcomes research.

- Outreach to the Society's more than 28,000 subscribers
- Jobs highlighted in the HEOR Career Center Connections
- Featured jobs in the Society's monthly eBulletin



Tuesday 11 September

7:00AM-5:00PM **REGISTRATION HELP DESK HOURS** Hana Foyer (4th fl)

7:15AM-8:15AM **EDUCATIONAL SYMPOSIUM** Nishiki Room (4th fl)



Value-Based Decision Making in Developing Countries: Multi-Criteria Decision Analysis (MCDA) for Off-Patent Pharmaceuticals

Developing countries often have challenges managing healthcare budgets without compromising effectiveness and safety of pharmaceuticals. In this session, value-based decision making for off-patent products and adaptation experiences in different developing countries (Indonesia, Vietnam, Kazakhstan, and Kuwait) will be discussed. *Sponsored by Abbott Established Pharmaceuticals Division (EPD)*

8:30AM-10:15AM **WELCOME & THIRD PLENARY SESSION** Concord Ballroom (5th fl)

Welcome from ISPOR Asia Consortium Executive Committee Chair

Isao Kamae, MD, DrPH, The University of Tokyo, Tokyo, Japan

ISPOR Distinguished Service Awards

Presented by: Federico Augustovski, MD, MSc, PhD, ISPOR President (2018-2019)

Awardees:

Takashi Fukuda, PhD, ISPOR Asia Pacific 2018 Conference Co-Chair

Shinya Saito, MD, PhD, ISPOR Asia Pacific 2018 Conference Co-Chair

Shunya Ikeda, MD, MS, DrMedSci, ISPOR Asia Pacific 2018 Program Committee Co-Chair

Kun Zhao, MD, PhD, MHSc, ISPOR Asia Pacific 2018 Program Committee Co-Chair

Isao Kamae, MD, DrPH, ISPOR Asia Consortium Executive Committee Chair (2016-2018)

Sukyeong Kim, PhD, ISPOR HTA Roundtable Asia-Pacific Chair (2016-2019)

2018 ISPOR Value in Health Regional Issues (Asia) Excellent Article Award

Presented by: Federico Augustovski, MD, MSc, PhD, ISPOR President (2018-2019) and Institute for Clinical Effectiveness and Health Policy (IECS-CONICET), Buenos Aires, Argentina

Awardee:

Eui-Kyung Lee, PhD, Sungkyunkwan University, Jangan-gu, Suwon, Gyeonggi-do, South Korea

ISPOR Asia Pacific 2020 Announcement

Nancy S. Berg, CEO and Executive Director, ISPOR, Lawrenceville, NJ, USA

Third Plenary Session: Risk-Sharing Agreements: Country Experiences, Challenges, and Lessons Learned

Moderator: Jörg Mahlich, Head Health Economics and Outcomes Research, Janssen Pharmaceutical, and Formal Director, Health Economics in Janssen Japan KK, Neuss, Germany

Speakers: Elizabeth de Somer, Chief Executive Officer, Medicines Australia, Canberra, Australia; **Jang Sae Rak**, Deputy Director, Pharmaceutical Listing Division, Pharmaceutical Benefit Department, Health Insurance Review and Assessment Service, Seoul, South Korea; **Gergana Zlateva, PhD**, Vice President, Global Market Access-Oncology, Global Health & Value, Pfizer Inc., New York, NY, USA

8:30AM-1:45PM **RESEARCH POSTER PRESENTATIONS - SESSION IV** Hana Ballroom (4th fl)

10:15AM-10:45AM **BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION IV** Hana Ballroom (4th fl)

10:45AM-11:45AM **BREAKOUT SESSION**

IP13: MCDA in HTA: Would MCDA Be a Valuable Addition to the Current Japanese HTA System?

Concord Ballroom A (5th fl)

Moderator: Isao Kamae, MD, DrPH, The University of Tokyo, Graduate School of Public Policy, Tokyo, Japan

Panelists: Omer Saka, MD, MSc, Deloitte Belgium, Zaventem, Belgium; **Ataru Igarashi, PhD**, The University of Tokyo, Tokyo, Japan; **Yot Teerawattananon, PhD**, HITAP, Nonthaburi, Thailand

IP14: Managed Entry Schemes: Hype vs Reality Concord Ballroom B (5th fl)

Moderator: Joshua Byrnes, PhD, Griffith University, Brisbane, Australia

Panelists: Jonathan Karnon, PhD, The University of Adelaide, Adelaide, Australia; **Jeonghoon Ahn, PhD**, Ewha Womans University, Seoul, Republic of South Korea; **Greg Cook, PhD**, Bristol Myers Squibb, Mulgrave, Australia

Tuesday 11 September

IP15: Current Practices and Prospects in Managing Reimbursement in Asia Pacific and Europe: What More Can We Do to Bridge the Experience and Expectation? *Concord Ballroom C (5th fl)*

Moderator: **Adrian Griffin, MSc**, Johnson & Johnson, Buckinghamshire, UK

Panelists: **Zhao Kun, MD, PhD, MHSc**, Division of Health Technology, Beijing, China; **Nathorn Chaiyakunapruk, PharmD, PhD**, Naresuan University, Phitsanulok, Thailand; **Onozaki Kohei, MS**, Health and Global Policy Institute, Tokyo, Japan

W13: Modeling Disease Progression and Economic Outcomes of Dementia Interventions: Exploring Options for a Complex Health Problem *Nishiki Room (4th fl)*

Discussion Leaders: **Kim-Huong Nguyen, PhD**, University of Queensland, Brisbane, Australia; **Brendan Mulhern, MRes**, University of Technology Sydney, Sydney, Australia; **Tracy Comans, PhD**, University of Queensland, Brisbane, Australia; **Jasmine Pwu, PhD**, MOHW, Taipei, Taiwan

W14: Delayed Access for Patients with Rare Diseases in Asia Pacific: Finding a Solution that Works

Ohgi Room (4th fl)

Discussion Leaders: **Annabel Griffiths, PhD**, Costello Medical, Cambridge, UK; **Ming-Chin Yang, PhD**, National Taiwan University, Public Health, Taipei, Taiwan; **Shanlian Hu, MD, MSc**, Shanghai Health Development Research Center, Shanghai, China; **Bertram Haeussler, MD**, IGES Institut GmbH, Berlin, Germany

P10: Cost-Effectiveness Studies *Grace Room (3rd fl)*

Moderator: **Ya-Chen Tina Shih, PhD**, Professor of Health Economics, & Section Chief, Section of Cancer Economics and Policy, Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

10:45AM-11:00AM

CE1 Cost-Effectiveness of Rivaroxaban and Aspirin Compared to Aspirin Alone in Patients with Stable Cardiovascular Disease: An Australian Perspective

Ademi Z, Zomer E, Tonkin A, Liew D, Monash University, Melbourne, Australia

11:00AM-11:15AM

CE2 Cost-Effectiveness of an Adherence-Enhancing Intervention for Patients With Gout Based on Real-World Data

Lin LW¹, Teng GG², Lim AY², Yoong JS¹, Wee HL¹, ¹National University of Singapore, Singapore, ²National University Health System, Singapore, Singapore

11:15AM-11:30AM

CE3 Cost-Effectiveness of Vedolizumab for the Management of Moderate-to-Severe Ulcerative Colitis in Thailand

Sruamsiri R, Takeda (Thailand) Ltd, Bangkok, Thailand

11:30AM-11:45AM

CE4 Cost-Effectiveness of Ticagrelor Compared with Clopidogrel in Patients With Acute Coronary Syndrome from a Vietnamese Healthcare Payers' Perspective

Do VD¹, Nguyen TT², Mellstrom C³, Nguyen QT⁴, Pham MH⁵, Hoang VS¹, Phuong LT⁶, Nguyen TT⁶, Luu TC⁶, ¹University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh, Viet Nam, ²University of Medicine and Pharmacy in HCMC, Ho Chi Minh City, Viet Nam, ³ASTRAZENECA, Gothenburg, Sweden, ⁴Hanoi Heart Hospital, Ha Noi, Viet Nam, ⁵Bach Mai Hospital, Ha Noi, Viet Nam, ⁶ASTRAZENECA, Ho Chi Minh, Viet Nam

11:45AM-2:45PM

LUNCH, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION IV *Hana Ballroom (4th fl)*

12:15PM-1:15PM

EDUCATIONAL SYMPOSIUM *Nishiki Room (4th fl)*



Challenges and Opportunities in Value Assessment of Biologic Medicines

The theme of the symposium will focus on value assessment of innovative biologic medicines, particularly to discuss how the value of innovative biologic medicines should be appropriately assessed from clinical, economic and humanistic perspective.

Sponsored by Amgen, Inc

12:45PM-1:45PM

RESEARCH POSTER AUTHOR DISCUSSION HOUR - SESSION IV *Hana Ballroom (4th fl)*

1:00PM-2:00PM

ISPOR NEW PROFESSIONAL EVENT – CAREER ADVICE ACROSS THE GLOBE “PUBLISHING OPPORTUNITIES IN HEOR” *Ensemble Room (44th fl)*

We invite ISPOR New Professional members, and soon-to-graduate student members, to attend the first ever Career Advice Across the Globe event to be hosted at an ISPOR Asia Pacific conference. Building on the success of the events held at the ISPOR Annual Conferences in the US and Europe, we are pleased to introduce this event for those who are new to the field to receive career advice from seasoned HEOR professionals. This installment will be a roundtable style event that focuses on the topic of “Publishing Opportunities in HEOR.” The session will feature speakers from *Value in Health* and *Value in Health Regional Issues* and attendees will have the opportunity to ask questions about how to maximize their potential of being published.

Tuesday 11 September

1:30PM-2:30PM

EDUCATIONAL SYMPOSIUM *Nishiki Room (4th fl)*



The Dynamic Constraints and Future Direction of Healthcare Reform in Japan

This session will focus on the financial constraints driving healthcare reform in Japan, as well as ensuring the effectiveness of health technology assessment (HTA) - process, assessment, and results. We will also discuss the importance of healthcare reform and our view of the future.

Sponsored by Takeda Pharmaceutical Company Limited.

2:45PM-3:45PM

BREAKOUT SESSION

IP16: Does Transparency Help or Hinder Emerging HTA Systems? *Concord Ballroom A (5th fl)*

Moderator: Wrik Ghosh, MSc, Costello Medical, Singapore, Singapore

Panelists: Thomas Butt, PhD, Peking University, Beijing, China; Fiona Pearce, MPH, Agency for Care Effectiveness, Ministry of Health, Singapore, Singapore; Brenda Pote, Group Market Access Manager, Roche Singapore Pte. Ltd., Singapore, Singapore

IP17: How Collaborative Can Companies Be in Developing Evidence to Support Market Access?

Concord Ballroom B (5th fl)

Moderator: Josie Godfrey, MA, JG Zebra Consulting, London, UK

Panelists: David Pearce, BPharm, MSc, Takeda Pharmaceuticals, Singapore, Singapore; Klair Bayley, BSc, Save Our Sons Duchenne Foundation, Hurlstone Park, Australia; Anthony Hatswell, MSc, Delta Hat, Nottingham, UK

IP18: How to Deal with Model Uncertainty at the Planning Stage of Cost-Effectiveness Analysis: Tips from Global Experiences *Concord Ballroom C (5th fl)*

Moderator: Bruno Rossi, BA, Satoru GK, Nishinomiya, Japan

Panelists: George Papadopoulos, GradDipEpi, Lucid Health Consulting Pty. Ltd., NSW, Australia; Joe Caputo, BSc, Vista Health Pte Ltd., Singapore, Singapore; Emiko Yoshida, MSc, Healthcare to All, Tokyo, Japan

W15: Dynamic Adjustment Mechanism for National Drug Formulary: International Experiences and the Development in China *Nishiki Room (4th fl)*

Discussion Leaders: Jiu-Hong Wu, PhD, PharmD, The 306th Hospital of PLA, Beijing, China; Feng Xie, BSc MSc PhD, McMaster University, Hamilton, ON, Canada; Fei-Li Zhao, BPharm, MS, PhD, Beijing Health Economics Association, Beijing, China

W16: The Application of Indication Based Pricing to Regenerative Medicine Therapies: An Interactive Workshop *Ohgi Room (4th fl)*

Discussion Leaders: Diana Brixner, PhD, RPh, FAMCP, University of Utah, Salt Lake City, UT, USA; Masayuki Yamato, PhD, Tokyo Women's Medical University, Tokyo, Japan; Mime Egami, BA, University of Utah, Salt Lake City, UT, USA; Michael Drummond, MCom, DPhil, University of York, Heslington, York, UK

PP11: Utility and Patient Preference Studies *Grace Room (3rd fl)*

Moderator: Jing Wu, PhD, Tianjin University, Tianjin, China

2:45PM-3:00PM

PP1 Consumer Preferences for Nutraceuticals: Pilot-Testing for Discrete Choice Experiment

Teoh SL¹, Ngorsuraches S², Chaiyakunapruk N³, ¹Monash University Malaysia, Selangor, Malaysia, ²South Dakota State University, Brookings, SD, USA, ³Monash University, Petaling Jaya, Malaysia

3:00PM-3:15PM

PP2 Are Time Trade-Off Values of Worse-Than-Death Health States Valid?

Gandhi M¹, Rand K², Luo N³, ¹Singapore Clinical Research Institute, Singapore, Singapore, ²University of Oslo, Oslo, Norway, ³National University of Singapore, Singapore

3:15PM-3:30PM

PP3 Patient Preference Study on Treatments of Non Small Cell Lung Cancer in Western China

Zhou N¹, Liu F¹, Hu M¹, Wang J¹, Yang N¹, Chen Y², Sun H², ¹Sichuan University, Chengdu, China, ²Fudan University, Shanghai, China

3:30PM-3:45PM

PP4 A Novel, Simple and Accurate Method to Map Quality-of-Life Scores to Utility Values

Cheung YB¹, Wee HL², Khoo EY³, Chong BK³, Yeo KK⁴, Lee CF⁵, Ng R⁶, Luo N², ¹Duke-NUS Medical School, Singapore, Singapore, ²National University of Singapore, Singapore, ³National University Hospital System, Singapore, Singapore, ⁴National Heart Center, Singapore, Singapore, ⁵University of Hong Kong, Hong Kong, China, ⁶National Cancer Center, Singapore, Singapore

4:00PM-5:00PM

BREAKOUT SESSION

IP19: Overdiagnosis and Its Excess Cost for Cancer Screening *Concord Ballroom A (5th fl)*

Moderator: Tony Hsiu-Hsi Chen, PhD, National Taiwan University, Taipei, Taiwan

Panelists: Amy Ming-Fang Yen, PhD, Taipei Medical University, Taipei, Taiwan; Sherry Yueh-Hsia Chiu, PhD, Chang Gung University, Taoyuan, Taiwan; Chisato Hamashima, MD, Teikyo University, Tokyo, Japan

Tuesday 11 September

IP20: Discrete Choice Experiments as a Measure of Social Value and Preferences: Application to Policy Making in Asia Pacific *Concord Ballroom B (5th fl)*

Moderator: **Brendan Mulhern, MRes**, University of Technology Sydney, Sydney, Australia

Panelists: **Stephen Goodall, BSc, MSc, PhD**, University of Technology Sydney, Sydney, Australia; **Timothy Bolt, PhD**, Saitama University, Saitama, Japan; **Ruoyan Gai, PhD**, National Center for Child Health and Development of Japan, Tokyo, Japan

IP21: Does Overseas Experience of Managed Entry Agreements Inform the New Japanese Pricing Scheme for Medical Devices? *Concord Ballroom C (5th fl)*

Moderator: **Michael F. Drummond, MCom, DPhil**, University of York, York, UK

Panelists: **Makoto Tamura, PhD**, International University of Health and Welfare, Ohtawara City, Japan; **Kosuke Kato, PhD**, American Medical Devices and Diagnostics Manufacturers' Association, Nakano-ku, Japan

W17: How E-Connected Medicine Will Change the Value of Pharmaceuticals *Nishiki Room (4th fl)*

Discussion Leaders: **Taishiro Kishimoto, MD, PhD**, Keio University, School of Medicine, Tokyo, Japan; **Ataru Igarashi, PhD**, University of Tokyo, Graduate School of Pharmaceutical Sciences, Tokyo, Japan; **Yasuko Aitoku, BS**, Bayer Yakuin Ltd., Osaka, Japan; **Mondher Toumi, MD, PhD, MSc**, Aix-Marseille University, Marseille, France

W18: Value of Information Analysis: Principles, Applications, and Good Practice Recommendations

Ohgi Room (4th fl)

Discussion Leaders: **Haitham Tuffaha, BPharm, MBA, MSc, PhD**, Griffith University, Brisbane, Australia; **Lotte Steuten, PhD, MSc**, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

P12: Drug Use and Disease Management Studies *Grace Room (3rd fl)*

Moderator: **Eui-Kyung Lee, PhD, RPh**, Sungkyunkwan University, Seoul, South Korea

4:00PM-4:15PM

DU1 Early Initiation of Long-Acting Injectable Antipsychotic Treatment Is Associated with Lower Healthcare Resource Use and Costs in Patients with Schizophrenia

Munday JS¹, Broder MS¹, Chang E¹, Hartry A², Yan T¹, **Greene M³**, ¹Partnership for Health Analytic Research, LLC, Beverly Hills, CA, USA, ²Lundbeck, Deerfield, IL, USA, ³Otsuka Pharmaceutical Development & Commercialization Inc., Princeton, NJ, USA

4:15PM-4:30PM

DU2 Star Analysis of Value for Money for Use of Oral Anticoagulants

Orlowski A¹, Ashton R¹, Glover R², ¹Imperial College Health Partners, London, UK, ²North England Commissioning Unit, Durham, UK

4:30PM-4:45PM

DU3 Why Aren't You Prescribing My Drug? Physician Concerns of Biologics for Rheumatoid Arthritis in China

Furnback W¹, Wang BC², ¹Evipoint, LLC, Point Pleasant, NJ, USA, ²Elysia Group, LLC, New York, NY, USA

4:45PM-5:00PM

DU4 The Impact of Glycemic Control on Cognition in People with Type 2 Diabetes

Hammad MA¹, Sulaiman SA¹, Aziz NA², Zaitoun M³, Mohamed Noor DA¹, ¹Universiti Sains Malaysia, Penang, Malaysia, ²Penang General Hospital, Penang, Malaysia, ³Armed Forces Hospitals Southern Region, Khamis Mushait, Saudi Arabia

ISPOR Conference Evaluation

We're listening.

Please complete a simple online evaluation after the conference to help us plan for future conferences. It's simple, answer 10 multiple-choice questions by Friday, September 28, 2018 using the ISPOR mobile app or on the ISPOR website at www.ispor.org.

Be a voice and help us plan for 2020.

ISPOR Session Evaluation

Have thoughts about a particular session? We're interested.

- Evaluate presentations through the ISPOR Mobile App
- Provide real-time responses immediately following the presentation
- 2-question evaluation for each presentation that can be accessed through the description portion of the presentation on the app.

Invitational Group Meetings

The following is a list of the *by invitation only* ISPOR group meetings during ISPOR Asia Pacific 2018. ISPOR members worldwide actively participate in ISPOR working groups to advance global health outcomes research and the use of this research in healthcare decisions. These ISPOR groups provide an opportunity for members to contribute to translating outcomes research into healthcare decisions.

Please note: invitees will receive an email reminder and notification of any changes to this ISPOR group meeting schedule

SATURDAY, SEPTEMBER 8, 2018

8:00AM-3:30PM	ISPOR HTA Roundtable Asia Pacific	Grace (3rd fl)
---------------	-----------------------------------	----------------

SUNDAY, SEPTEMBER 9, 2018

8:00AM-12:30PM	ISPOR Patient Representatives Roundtable Asia Pacific	Nishiki (4th fl)
8:30AM-12:30PM	Educational Forum - Funding Rare Diseases in Asia Pacific: Value Assessment and Budget Impact <i>(supported by an educational grant from Shire)</i>	Ohgi (4th fl)
3:30PM-7:30PM	Educational Forum – Visualizing Future through Cancer Immunotherapies <i>(supported by an educational grant from Roche)</i>	Fuji (42nd fl)
3:45PM-4:45PM	ISPOR Asia Consortium / ViHRI Leadership	Takao (42nd fl)
3:45PM-4:45PM	ISPOR Korea Chapter	Harmony (44th fl)
5:00PM-6:00PM	ISPOR Chinese Speaking Chapters	Takao (42nd fl)

MONDAY, SEPTEMBER 10, 2018

10:30AM-11:30AM	ISPOR Indian Chapter	Harmony (44th fl)
10:30AM-11:30AM	ISPOR Thailand Chapter	Fuji (42nd fl)
1:00PM-5:00PM	Educational Forum – Sharing Risk to Drive Value and Access in Chronic Care <i>(supported by an educational grant from Boehringer Ingelheim)</i>	Harmony (44th fl)
2:15PM-3:15 PM	ISPOR Japan Chapter	Ensemble (44th fl)
5:00PM-6:00PM	ISPOR Australia and New Zealand Chapters	Fuji (42nd fl)
6:10PM-10:00PM	Leadership Evening Forum <i>(by invitation only)</i> <i>(sponsored by the University of Tokyo, Musashino University Institute for Global Affairs (MIGA), and the Canon Institute for Global Studies)</i>	Offsite

TUESDAY, SEPTEMBER 11, 2018

10:45AM-11:45AM	ISPOR Asia Consortium Industry Committee	Harmony (44th fl)
-----------------	--	-------------------



ISPOR

Improving healthcare decisions

ISPOR in Action in Asia Pacific Grow with us!



Through its local member groups, conferences, and region-specific publications, ISPOR provides a wide array of resources and tools to help all healthcare stakeholders in the region apply the best scientific methodologies to health economics and outcomes research.

Membership + Conferences

- 12% of ISPOR members are located in Asia Pacific countries
- 400% growth in attendance at ISPOR's Asia Pacific conferences since 2003

Asia Consortium and Regional Chapters

- 32 Regional Chapters in Asia Pacific
- 7 working committees
- In the past 14 years, the Asia Consortium has grown from 13 founding members to 1000 members, making a combined total of 3600 consortia and chapter members in the Asia Pacific region

Publications

- *Value in Health Regional Issues* publishes scientific, peer-reviewed research specific to the Asia Pacific region
- *News Across Asia* features health policy, regional initiatives, and member-reported news in a concise quarterly newsletter

Get Involved

- Attend Asia Pacific and other ISPOR conferences throughout the year
- Join Asia Consortium working groups
- Learn about Regional Chapters in Asia Pacific

505 Lawrence Square Blvd South, Lawrenceville, NJ 08648

©2018 ISPOR – The professional society for health economics and outcomes research

Grow with us!
Join ISPOR today.

ISPOR Asia Pacific 2018

8 – 11 September
Tokyo, Japan

Poster - Exhibit Program

Research Poster Presentations Overview

Exhibit Program Overview

Exhibitor Listing

Exhibit/Poster Hall Floor Plan

Research Poster Presentations Overview

Over 700 poster presentations will be on display during the conference in the Poster & Exhibit Hall *Hana Ballroom ABC (4th fl)*.

- Presenters are required to be with their posters during the Poster Author Discussion Hour.
- The poster hall is in rows (A-P) and each poster board is numbered accordingly (e.g. A1-P3)
- Each poster presentation is assigned a numbered board location, which is shown next to the poster presentation title. Please note this is different from the poster code (e.g. PHP1, PCV35), which was assigned to each poster presentation upon acceptance.
- Poster presentation titles and authors, as well as the numbered board location, are available on the myISPORTokyo.zerista.com web platform and mobile app. This information is also available as a PDF on the ISPOR website.
- Poster board numbering is available on the floor plan on page 34 and row locations (by topic) are available in the table below.

Poster Presentations Display Hours

POSTER PRESENTATION SESSIONS	POSTER LOCATION	PRESENTER SET UP TIME	POSTER DISPLAY HOURS	AUTHOR DISCUSSION HOUR	PRESENTER DISMANTLE TIME*
SESSION I: SUNDAY, 9 SEPTEMBER					
PMD: MEDICAL DEVICE/DIAGNOSTICS	Rows A-C	12:15PM -	12:30PM - 7:30PM	6:30PM - 7:30PM	7:30PM
PCN: CANCER	Rows C-K	12:30PM			
PMH: MENTAL HEALTH	Rows K-M				
PSS: SENSORY SYSTEMS DISORDERS	Rows N-P				
SESSION II: MONDAY, 10 SEPTEMBER					
PHP: HEALTHCARE USE & POLICY STUDIES	Rows A-H	8:15AM -	8:30AM - 1:30PM	12:30PM - 1:30PM	1:30PM
PGI: GASTROINTESTINAL DISORDERS	Rows H-I	8:30AM			
PIH: INDIVIDUAL'S HEALTH	Rows I-J				
PSY: SYSTEMIC DISORDERS/CONDITIONS	Rows K-M				
PUK: URINARY/KIDNEY DISORDERS	Rows M-O				
SESSION III: MONDAY, 10 SEPTEMBER					
PIN: INFECTION	Rows A-D	2:15PM -	2:30PM - 7:30PM	6:30PM - 7:30PM	7:30PM
PMS: MUSCULAR-SKELETAL DISORDERS	Rows D-F	2:30PM			
PMU: MULTIPLE DISEASES	Rows F-K				
PND: NEUROLOGICAL DISORDERS	Rows K-L				
PRS: RESPIRATORY-RELATED DISORDERS	Rows L-N				
SESSION IV: TUESDAY, 11 SEPTEMBER					
PRM: RESEARCH ON METHODS	Rows A-E	8:15AM -	8:30AM - 1:45PM	12:45PM - 1:45PM	1:45PM
PCV: CARDIOVASCULAR DISORDERS	Rows E-I	8:30AM			
PDB: DIABETES/ENDOCRINE DISORDERS	Rows J-M				
PCP: CONCEPTUAL PAPERS	Rows M-N				

*Posters that are not removed at the scheduled dismantle times will be discarded.

Exhibit Program Overview

Exhibit Viewing *Hana Ballroom (4th Floor)*

Sunday, 9 September 12:00PM-7:30PM

Monday, 10 September 8:30AM-7:30PM


Tuesday, 11 September 8:30AM-1:45PM

Exhibitor Directory

Company Name	Exhibit Table Location
Amaris Consulting UK Ltd	#23 (Hana Ballroom Lobby)
BaseCase	#10
Clinical Study Support, Inc.	#24 (Hana Ballroom Lobby)
Costello Medical Singapore Pte Ltd	#12
Creativ-Ceutical	#19
CRECON MEDICAL ASSESSMENT INC.	#4 & #5
GfK Health	#16
ICON	#9
IQVIA	#2 & #3
JMDC Inc.	#18
Kantar Health	#6 & #7
MAESTrO Database	#13
Medical Data Vision Co. Ltd.	#15
Normin Health	#17
Pharmerit International	#1
Prioritis Ltd	#11
RWS Life Sciences	#14
Syneos Health	#8

**Subject to change*

Exhibit/Poster Hall Floor Plan



Poster Presentations

Session I	Sunday, 9 September	12:00PM-7:30PM
Session II	Monday, 10 September	8:30AM-1:30PM
Session III	Monday, 10 September	2:30PM-7:30PM
Session IV	Tuesday, 11 September	8:30AM-1:45PM



*Before it became a medicine,
 It was 5,000 researched compounds.
 87 different protein structures.
 500,000 lab tests.
 1,600 scientists.
 80-hour workweeks.
 14 years of breakthroughs and setbacks.
 36 clinical trials.
 8,500 patient volunteers.
 And more problems to solve than we could count.
 Before it became a medicine,
 It was an idea in the mind of a Pfizer scientist.
 Now it's a medicine
 That saves lives every day.*



Driven to discover the cure



At Takeda Oncology, we endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients.

Learn more about our global commitment to oncology.
Visit us online at takedaoncology.com.

Takeda Oncology is the oncology business unit brand of Takeda Pharmaceutical Company Limited ©2017 Millennium Pharmaceuticals, Inc. All rights reserved.



HEOR Resources

- Good Practices for Outcomes Research
- Pharmacoeconomic Guidelines Around the World
- Global Healthcare Systems Road Maps
- Scientific Presentations Database
- International Digest of Databases
- Assessing the Evidence for Decision Makers
- Outcomes Research Guidelines Index
- Health Technology Assessment Central

Key Information

WI-FI AND MOBILE APP ACCESS

For the convenience of conference attendees, Wi-Fi is available in the hotel.

NETWORK: ISPOR / WI-FI PASSWORD: TOKYO2018

Wi-Fi is only intended for checking email and using the conference mobile app, not for downloading files. Connection speeds will vary depending on the volume of users.

Download the mobile app on your smartphone or tablet



Can't download the app? Use your web browser: <https://myISPORTokyo.zerista.com/>
Use the same details as used for the myISPORTokyo web pages. Your ISPOR mobile app account email address is the same email address used for your conference registration.

Need help? Select "Need help logging in?" on the login screen.

Mobile App Sponsored by HealthCore, Inc.



REGISTRATION DISCLAIMER

For security purposes all individuals must be registered and wear the official ISPOR Conference Name Badge to gain access to the conference, the sessions, the exhibit poster hall, and any other ISPOR activity. Onsite staff and security will monitor for name badges and will deny access if individual does not have an official ISPOR Conference Name Badge. Individuals not wearing a name badge will be directed to registration. Please note if you lose your name badge and need to have it re-printed you cannot print that at the self-serve station, you will need to visit the registration help desk.

Sharing of conference name badges is prohibited.

Because of the professional nature of the program and safety and liability concerns, guests and individuals under age 18 are not permitted access or to register for the conference. This includes access to the conference in general, to scientific presentations, and to the exhibit and poster hall.

LANGUAGE INFORMATION

All sessions at ISPOR Asia Pacific 2018 are presented in English. ISPOR regrets that due to the disruption to other delegates, whisper translation (chuchotage) is not permitted in any session, including short courses. To discuss options to meet educational needs in multiple languages, please contact meetingsinfo@ispor.org.

PRESENTATION SLIDES/POSTERS

Plenary session, issue panel, workshop, ISPOR forum, and symposia slides will be available via the conference app and at the ISPOR Asia Pacific 2018 Released Presentations page at www.ispor.org during/after the conference, subject to speaker approval.

The Released Presentations page will feature many of the conference's slide presentations as PDFs. In 2016, more than 80% of the presentations were available to the public during/after the conference. The Released Presentations page is accessible via the conference mobile app and at <https://www.ispor.org/Event/index/2018Tokyo>.

Podium and poster presentation abstracts and released slides or poster PDFs are available at the ISPOR Scientific Presentations Database (a searchable database of over 45,000 research papers presented at ISPOR conferences) at https://tools.ispor.org/RESEARCH_STUDY_DIGEST/research_index.asp.

SPEAKER INFORMATION

Upload the final version of your slide presentation in the Speaker Ready Room on the same day of your session!

All speakers are encouraged to use the Speaker Ready Room to preview their slide presentation and/or upload an updated version. Presentations submitted to ISPOR Speaker's Corner by the specified advance deadline and all presentations uploaded/updated in the Speaker Ready Room 30 minutes prior to the session will be pre-loaded to the computer in the session room. All speakers are expected to arrive at their presentation room 15 minutes prior to the session start time. ISPOR staff will be available in the session room to assist the presenter.

The speaker ready room is provided in Kaede (4th fl) with the following hours:

- Sunday, 9 September: 12:00PM-6:00PM
- Monday, 10 September: 8:00AM-6:00PM
- Tuesday, 11 September: 8:00AM-4:00PM



ISPOR RESEARCH PRESENTATION AWARDS

Awards are given for the best research presentations for podium presentations (up to 6) and for poster presentations (up to 6).

All research podium presentations are considered for an award. The top 10% of research poster presentations, based on abstract review score, are considered for a poster presentation award. These are identified with a rosette and will be judged during the conference.

Award recipients will be notified by mail and recognized on the ISPOR website at the

conclusion of the conference.

SOCIAL MEDIA

Communicating by way of social media is encouraged if it falls within embargo and



communications rules.

Be part of the live discussion!

- Tweet your comments to @ISPORorg during the conference using #ISPORTokyo
- Access expert insights and share your views on conference sessions at the ISPOR LinkedIn Discussion Group: <http://bit.ly/ISPOR-LIn>
- Network with your peers on the ISPOR Facebook page: <http://bit.ly/ISPOR-FB>

RECORDING & PRESS INFORMATION

ISPOR supports the promotion of research presented at ISPOR conferences, while safeguarding sensitive information, data, and research findings that are not yet available to the public. **Due to the sensitive nature of data—particularly preliminary, unpublished research findings—all filming and recording of scientific sessions and the poster hall are prohibited during the conference, without the express written consent of ISPOR.**

Portions of ISPOR Asia Pacific 2018 may be recorded by ISPOR – the professional society for health economics and outcomes research. By participating in the discussions, conference registrants agree that ISPOR may electronically copy, videotape, or audiotape their attendance at and involvement in any program. Registration and attendance at ISPOR Asia Pacific 2018 constitutes an agreement by the registrant to ISPOR's use and distribution (both now and in the future) of their image or voice in photographs, videotapes, electronic reproductions, and audiotapes of such events and activities. ISPOR will strictly enforce its rights as the exclusive licensee of all publication and reproduction rights to each presentation, and no presentation, in whole or in part, may be reproduced without approval from ISPOR.

Conference attendees must gain approval from a speaker or poster presenter prior to quoting or publishing that individual's scientific results. Members of the press must identify themselves as such before questioning speakers and conference attendees if using the information in a professional capacity.

More detailed information on ISPOR's Press Pass, Legal, and Embargo Policies are available on ISPOR's News & Press page at the ISPOR website (www.ispor.org).

For further questions on these policies, please contact: press@ispor.org

SAFETY AND RESPONSIBILITY POLICY

ISPOR is committed to providing a safe, productive, and welcoming environment for all participants and staff. All participants, including, but not limited to, attendees, speakers, volunteers, exhibitors, ISPOR staff, service providers, and others, are expected to abide by this Safety and Responsibility Policy as noted on our website under Attendee Information > Key Information.

CONFERENCE PROGRAM DISCLAIMER

Please be advised that while the conference program is designed to provide accurate information regarding the subject matter covered, the views, opinions, and recommendations expressed are those of the authors and speakers, not of ISPOR – the professional society for health economics and outcomes research, and thus ISPOR does not guarantee the accuracy of the information disseminated. If professional advice is desired, please consult a competent professional.

ANTITRUST COMPLIANCE

It is the unmediating policy of ISPOR to comply strictly with the letter and spirit of all local and U.S. Federal, State, and applicable international trade regulations and antitrust laws. Any activities of ISPOR or ISPOR-related actions of its officers, Executive Committee Members, or members that violate these regulations and laws are detrimental to the interests of ISPOR and are unequivocally contrary to ISPOR policy.

FINANCIAL DISCLOSURE INFORMATION

Research podium and poster presentation financial disclosure information will be available online at: <https://www.ispor.org/funding-statement> in *Value in Health* (Volume 21, Suppl 2) in September 2018. Faculty and staff involved in the planning or presentation of this conference are required to disclose all real or apparent commercial financial affiliations related to conference content. This information is available on request at the ISPOR Registration desk.

QUESTIONS & INFORMATION

Please ask ISPOR staff members for any additional information about the conference or about ISPOR. ISPOR staff can be identified by their ISPOR name badge.

TOP 10 HEOR TRENDS

1

DRUG PRICING AND SPENDING

Conversations on how to manage drug prices are intensifying, with a particular focus on ensuring that drug prices reflect the value of treatment.



2

INNOVATIVE AND CURATIVE THERAPIES

As drug discovery and healthcare move toward more personalized medical treatment, novel therapies will continue to be developed.



3

ACCELERATED DRUG APPROVALS

Regulatory efforts continue to speed the approval of new drugs that conquer unmet medical needs and get much-needed therapies to patients, yet in making them widely available, reimbursement is equally important.



4

UNIVERSAL HEALTH COVERAGE

Globally, a growing commitment to universal health coverage is elevating the role of HEOR.



5

AGING POPULATION


The world is getting older. By 2050, the number of people over 65 is expected to reach 1.5 billion. It is crucial that healthcare spending be managed to deliver outcomes most desired by our aging population.



6

mHEALTH

There is rising optimism about the potential of mHealth (mobile health) to cost-effectively improve patient care.



7

DIAGNOSTICS

With the launch of more advanced—and even more costly—therapies, the need for jointly developed diagnostics to ensure the right patients are benefiting from them has grown even more essential.



8

BIOSIMILARS

Biosimilars have the potential to give patients a wide variety of treatment options—and to provide savings to the entire healthcare system.



9

PREVENTIVE MEDICINE

Health economic evaluation is particularly important for preventive medicine that improves healthcare worldwide.



10


DISRUPTIVE INNOVATORS

In the past decade, scientific innovations in cell and gene research have been creating new therapies that pose novel challenges to those involved in health technology assessment and healthcare decision making.




Conference Rooms Floor Plans


5Fご案内




4Fご案内




3Fご案内




47Fご案内



44Fご案内



42Fご案内



ISPOR 2018 Conferences



ISPOR Dubai 2018

19-20 September 2018 / Dubai, United Arab Emirates

Healthcare Decision Making in the Middle East and North Africa: Role of Health Economics, Outcomes Research, and Health Technology Assessment

Register today.



ISPOR Summit

October 19, 2018 / Washington, DC, USA

New Approaches to Value Assessment – Towards More Informed Pricing in Healthcare

Hotel discounts through September 27, based on availability.



ISPOR Europe 2018

10-14 November 2018 / Barcelona, Spain

New Perspectives for Improving 21st Century Health Systems

Register by 25 September for savings.

ISPOR 2019 CONFERENCES



ISPOR 2019

**May 18-22, 2019
New Orleans, LA, USA**

*Abstract Submission Opens:
October 1, 2018*



ISPOR Latin America 2019

**12-14 September 2019
Bogotá, Colombia**

*Abstract Submission Opens:
1 December 2018*



ISPOR Warsaw 2019

**March 2019
Warsaw, Poland**

Details to come



ISPOR Europe 2019

**2-6 November 2019
Copenhagen, Denmark**

*Abstract Submission Opens:
1 March 2019*